CA2039420C - Treatment of cataract with 15-keto-prostaglandin compounds - Google Patents
Treatment of cataract with 15-keto-prostaglandin compoundsInfo
- Publication number
- CA2039420C CA2039420C CA002039420A CA2039420A CA2039420C CA 2039420 C CA2039420 C CA 2039420C CA 002039420 A CA002039420 A CA 002039420A CA 2039420 A CA2039420 A CA 2039420A CA 2039420 C CA2039420 C CA 2039420C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- keto
- dihydro
- give
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000002177 Cataract Diseases 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 249
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 71
- 125000005843 halogen group Chemical group 0.000 claims abstract description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 10
- 239000003085 diluting agent Substances 0.000 claims abstract description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 5
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 14
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 description 72
- 239000000243 solution Substances 0.000 description 68
- -1 -isopropyl ester Chemical class 0.000 description 65
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- 238000012360 testing method Methods 0.000 description 59
- 239000011369 resultant mixture Substances 0.000 description 53
- 238000000034 method Methods 0.000 description 50
- 150000002148 esters Chemical class 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 30
- 125000004432 carbon atom Chemical group C* 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- BKONIFYZHZUXLS-UHFFFAOYSA-N 6-carboxyhexylphosphanium;bromide Chemical compound [Br-].OC(=O)CCCCCC[PH3+] BKONIFYZHZUXLS-UHFFFAOYSA-N 0.000 description 23
- 238000010898 silica gel chromatography Methods 0.000 description 23
- 239000002504 physiological saline solution Substances 0.000 description 22
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 21
- 239000012043 crude product Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 13
- 150000002576 ketones Chemical group 0.000 description 13
- HOJNQHKCNPGJGJ-YLIIVCRJSA-N phenacyl (z)-9-[(1r,2r,3r)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]non-7-enoate Chemical compound CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCCCC(=O)OCC(=O)C1=CC=CC=C1 HOJNQHKCNPGJGJ-YLIIVCRJSA-N 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 11
- 210000000695 crystalline len Anatomy 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 150000001299 aldehydes Chemical class 0.000 description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 9
- 229920000858 Cyclodextrin Polymers 0.000 description 8
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 102100034195 Thrombopoietin Human genes 0.000 description 8
- 229960000711 alprostadil Drugs 0.000 description 8
- 229940097362 cyclodextrins Drugs 0.000 description 8
- 229960002986 dinoprostone Drugs 0.000 description 8
- 229930182830 galactose Natural products 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 150000004702 methyl esters Chemical class 0.000 description 8
- 229940073584 methylene chloride Drugs 0.000 description 8
- 239000012046 mixed solvent Substances 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 description 7
- 241000700157 Rattus norvegicus Species 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 239000012300 argon atmosphere Substances 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- IASRMNRQZIRYHM-UHFFFAOYSA-N 6-carboxyhexyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCCC(=O)O)C1=CC=CC=C1 IASRMNRQZIRYHM-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000006859 Swern oxidation reaction Methods 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 6
- NSCXBOBVIXPOPW-NWCIEGOKSA-N propan-2-yl (z)-9-[(1r,2r,3r,5s)-2-[2-(2-heptyl-1,3-dioxolan-2-yl)ethyl]-5-hydroxy-3-(oxan-2-yloxy)cyclopentyl]non-7-enoate Chemical compound C([C@@H]1[C@H]([C@@H](O)C[C@H]1OC1OCCCC1)C\C=C/CCCCCC(=O)OC(C)C)CC1(CCCCCCC)OCCO1 NSCXBOBVIXPOPW-NWCIEGOKSA-N 0.000 description 6
- QBEDUXZCSTWZTP-KCZVDYSFSA-N propan-2-yl 9-[(1r,2r,3r)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]nonanoate Chemical compound CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCCCC(=O)OC(C)C QBEDUXZCSTWZTP-KCZVDYSFSA-N 0.000 description 6
- FTCKOEKJNDVBJD-MUNZXYLSSA-N (3ar,4r,5r,6as)-4-(4,4-difluoro-5-oxooctyl)-5-(oxan-2-yloxy)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one Chemical compound O([C@H]1[C@@H]([C@H]2CC(=O)O[C@H]2C1)CCCC(F)(F)C(=O)CCC)C1CCCCO1 FTCKOEKJNDVBJD-MUNZXYLSSA-N 0.000 description 5
- 101150041968 CDC13 gene Proteins 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- REPVRVIBFFXYLH-DKHJWVMHSA-N methyl (z)-9-[(1r,2r,3r,5s)-2-(4,4-difluoro-3-oxooctyl)-3,5-dihydroxycyclopentyl]non-7-enoate Chemical compound CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCCCC(=O)OC REPVRVIBFFXYLH-DKHJWVMHSA-N 0.000 description 5
- YRKODSCXNKWHGO-GHMGVUHVSA-N phenacyl (z)-9-[(1r,2r,3r)-2-(4,4-difluoro-3-oxooctyl)-3-(oxan-2-yloxy)-5-oxocyclopentyl]non-7-enoate Chemical compound C([C@H]1C(=O)C[C@H]([C@@H]1CCC(=O)C(F)(F)CCCC)OC1OCCCC1)\C=C/CCCCCC(=O)OCC(=O)C1=CC=CC=C1 YRKODSCXNKWHGO-GHMGVUHVSA-N 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- 238000006809 Jones oxidation reaction Methods 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- 229940102223 injectable solution Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- NFUUAVFPTHMLHW-VOQKXKRBSA-N propan-2-yl (z)-9-[(1r,2r,3r,5s)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]non-7-enoate Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCCCC(=O)OC(C)C NFUUAVFPTHMLHW-VOQKXKRBSA-N 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- UEJICTILJZKHQY-MUNZXYLSSA-N (3ar,4r,5r,6as)-4-(4,4-difluoro-3-oxooctyl)-5-(oxan-2-yloxy)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one Chemical compound O([C@H]1[C@@H]([C@H]2CC(=O)O[C@H]2C1)CCC(=O)C(F)(F)CCCC)C1CCCCO1 UEJICTILJZKHQY-MUNZXYLSSA-N 0.000 description 3
- CORRAXPZMWTYIP-LPGFFSAWSA-N (3ar,4r,5r,6as)-4-(hydroxymethyl)-5-(oxan-2-yloxy)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one Chemical compound O([C@H]1[C@H]([C@H]2CC(=O)O[C@H]2C1)CO)C1CCCCO1 CORRAXPZMWTYIP-LPGFFSAWSA-N 0.000 description 3
- BXSCNNADPQDDOK-HYPYWDQKSA-N (3ar,4r,5r,6as)-4-[(e)-4,4-difluoro-5-oxooct-2-enyl]-5-(oxan-2-yloxy)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one Chemical compound O([C@H]1[C@@H]([C@H]2CC(=O)O[C@H]2C1)C/C=C/C(F)(F)C(=O)CCC)C1CCCCO1 BXSCNNADPQDDOK-HYPYWDQKSA-N 0.000 description 3
- JLPQXFFMVVPIRW-UHFFFAOYSA-N 7-bromoheptanoic acid Chemical compound OC(=O)CCCCCCBr JLPQXFFMVVPIRW-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- CZEBTZMIQZVUSE-UHFFFAOYSA-N [6-cyano-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid Chemical compound C1=C(C#N)C=C2N(C(=O)OC(C)(C)C)C(B(O)O)=CC2=C1 CZEBTZMIQZVUSE-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000002596 lactones Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940054534 ophthalmic solution Drugs 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- XTHLWLJWJINZOO-NKALFCTASA-N (3aR,4R,5R,6aS)-4-(3-tert-butyl-4,4-difluoro-8-methyl-8-silyloxynonyl)-5-(oxan-2-yloxy)-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]furan-2-ol Chemical compound C(C)(C)(C)C(CC[C@@H]1[C@H]2CC(O[C@H]2C[C@H]1OC1OCCCC1)O)C(CCCC(O[SiH3])(C)C)(F)F XTHLWLJWJINZOO-NKALFCTASA-N 0.000 description 2
- LEWMANYBGYSQMC-GMIZXNJASA-N (3aR,4R,5R,6aS)-4-hydroxy-6a-methyl-5-(oxan-2-yloxy)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]furan-2-one Chemical compound O[C@@H]1[C@H]2CC(O[C@]2(C[C@H]1OC1OCCCC1)C)=O LEWMANYBGYSQMC-GMIZXNJASA-N 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- CISDEVRDMKWPCP-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3,3-difluoroheptan-2-one Chemical compound CCCCC(F)(F)C(=O)CP(=O)(OC)OC CISDEVRDMKWPCP-UHFFFAOYSA-N 0.000 description 2
- RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 description 2
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KZGNJLHBTZMSMD-UHFFFAOYSA-N C[Cu]C Chemical compound C[Cu]C KZGNJLHBTZMSMD-UHFFFAOYSA-N 0.000 description 2
- 239000012027 Collins reagent Substances 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101150020741 Hpgds gene Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 241000047703 Nonion Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical group CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940069265 ophthalmic ointment Drugs 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000005023 xylyl group Chemical group 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- NIRHEUUFSAUPIO-TWUSMTIXSA-N (z)-9-[(1r,2r,3r)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]non-7-enoic acid Chemical compound CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCCCC(O)=O NIRHEUUFSAUPIO-TWUSMTIXSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical class CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- BCRKBAANNQLPBT-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3,3-difluorononan-2-one Chemical compound CCCCCCC(F)(F)C(=O)CP(=O)(OC)OC BCRKBAANNQLPBT-UHFFFAOYSA-N 0.000 description 1
- LQZCYXCHWNQBKX-UHFFFAOYSA-N 1-dimethoxyphosphorylheptan-2-one Chemical compound CCCCCC(=O)CP(=O)(OC)OC LQZCYXCHWNQBKX-UHFFFAOYSA-N 0.000 description 1
- VXPBDCBTMSKCKZ-XQHNHVHJSA-N 15-dehydro-prostaglandin E1 Chemical compound CCCCCC(=O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O VXPBDCBTMSKCKZ-XQHNHVHJSA-N 0.000 description 1
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- GLIZUTURRHNTMF-UHFFFAOYSA-N 6-carboxyhex-2-enyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC=CCCCC(=O)O)C1=CC=CC=C1 GLIZUTURRHNTMF-UHFFFAOYSA-N 0.000 description 1
- WCZUXNBRBZFNPY-UHFFFAOYSA-N 6-carboxyhex-3-enyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCC=CCCC(=O)O)C1=CC=CC=C1 WCZUXNBRBZFNPY-UHFFFAOYSA-N 0.000 description 1
- HVVQSKCGHAPHMV-UHFFFAOYSA-N 7-bromoheptanenitrile Chemical compound BrCCCCCCC#N HVVQSKCGHAPHMV-UHFFFAOYSA-N 0.000 description 1
- FMKNXQAUFDRBNP-UHFFFAOYSA-N CCCCCC(COP(O)=O)=O Chemical compound CCCCCC(COP(O)=O)=O FMKNXQAUFDRBNP-UHFFFAOYSA-N 0.000 description 1
- 101100310593 Candida albicans (strain SC5314 / ATCC MYA-2876) SOD4 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 206010007766 Cataract traumatic Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NGRZMGCGHOSCBJ-UHFFFAOYSA-N OC(CCCCC(C=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1)=O.Br Chemical compound OC(CCCCC(C=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1)=O.Br NGRZMGCGHOSCBJ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 description 1
- 206010037756 Radiation cataract Diseases 0.000 description 1
- 101100190148 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGA2 gene Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010044135 Toxic cataract Diseases 0.000 description 1
- 231100000329 Toxic cataract Toxicity 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- QUXMPZUVBXHUII-UHFFFAOYSA-N [1,1-bis(hydroxymethylamino)ethylamino]methanol Chemical class OCNC(C)(NCO)NCO QUXMPZUVBXHUII-UHFFFAOYSA-N 0.000 description 1
- MRZAUHPKRKMSPG-UHFFFAOYSA-K [F-].[F-].[F-].C(CCC)[N+](CCCC)(CCCC)CCCC.C(CCC)[N+](CCCC)(CCCC)CCCC.C(CCC)[N+](CCCC)(CCCC)CCCC Chemical compound [F-].[F-].[F-].C(CCC)[N+](CCCC)(CCCC)CCCC.C(CCC)[N+](CCCC)(CCCC)CCCC.C(CCC)[N+](CCCC)(CCCC)CCCC MRZAUHPKRKMSPG-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000004699 copper complex Chemical class 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 125000002592 cumenyl group Chemical group C1(=C(C=CC=C1)*)C(C)C 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 238000006704 dehydrohalogenation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- DZFYOYRNBGNPJW-UHFFFAOYSA-N ethoxythallium Chemical compound [Tl+].CC[O-] DZFYOYRNBGNPJW-UHFFFAOYSA-N 0.000 description 1
- OFGLXRANLNLCHY-HBMCJLEFSA-N ethyl 7-[(1r,2s,3s)-3-hydroxy-2-(7-methyl-3-oxooctyl)-5-oxocyclopentyl]-6-oxoheptanoate Chemical group CCOC(=O)CCCCC(=O)C[C@@H]1[C@H](CCC(=O)CCCC(C)C)[C@@H](O)CC1=O OFGLXRANLNLCHY-HBMCJLEFSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- CBZINEMIDCLHAY-SNHXEXRGSA-N methyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxononyl)cyclopentyl]hept-5-enoate Chemical group CCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC CBZINEMIDCLHAY-SNHXEXRGSA-N 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003822 preparative gas chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- RRUYLMFSYDCRIZ-ADMXILSSSA-N propan-2-yl (z)-9-[(1r,2r,3r)-3-hydroxy-5-oxo-2-(3-oxodecyl)cyclopentyl]non-7-enoate Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCCCC(=O)OC(C)C RRUYLMFSYDCRIZ-ADMXILSSSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MYHXHCUNDDAEOZ-FOSBLDSVSA-N prostaglandin A2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MYHXHCUNDDAEOZ-FOSBLDSVSA-N 0.000 description 1
- QLPYHQHJKMTHED-UHFFFAOYSA-N prostaglandin E1 methyl ester Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(=O)OC QLPYHQHJKMTHED-UHFFFAOYSA-N 0.000 description 1
- WGCXTGBZBFBQPP-UHFFFAOYSA-N prostaglandin E2 methyl ester Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(=O)OC WGCXTGBZBFBQPP-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 201000008525 senile cataract Diseases 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Abstract
A pharmaceutical composition for treatment of cataract comprising a 15-ketoprostaglandin compound in association with a pharmaceutically acceptable carrier, diluent or excipient, of the general formula:
(I) wherein L and M are hydrogen atom, hydroxy, lower alkyl, hydroxy(lower)alkyl or oxo, provided that at least one of L
and M is not hydrogen atom and that the five-membered ring may have one or two doubl.e bonds, Q1 and Q2 are hydrogen atom, halogen atom or lower alkyl, D is -CH2-CH2-, -CH=CH-, -CC-or -CO-CH2-, E is -CH2-CH2- or -CH=CH-, W is -CH2-CH2-CH2-, -CH=CH-CH2 or -CH2-CH=CH-, Ra is hydrogen atom, lower alkyl, lower cycloalkyl, monocyclic aryl, monocyclic aryl(lower)alkyl or monocyclic aroyl(lower)alkyl, Rb is single bond or lower alkylene, Rc is lower alkyl which is unsubstituted or substituted with halogen, lower cycloalkyl which is unsubstituted or substituted with lower alkyl, monocyclic aryl which is unsubstituted or substituted with halogen or halo(lower)alkyl, or monocyclic aryloxy which is unsubstituted or substituted with halogen or halo(lower)alkyl, or a pharmaceutically acceptable salt when Ra is hydrogen atom.
(I) wherein L and M are hydrogen atom, hydroxy, lower alkyl, hydroxy(lower)alkyl or oxo, provided that at least one of L
and M is not hydrogen atom and that the five-membered ring may have one or two doubl.e bonds, Q1 and Q2 are hydrogen atom, halogen atom or lower alkyl, D is -CH2-CH2-, -CH=CH-, -CC-or -CO-CH2-, E is -CH2-CH2- or -CH=CH-, W is -CH2-CH2-CH2-, -CH=CH-CH2 or -CH2-CH=CH-, Ra is hydrogen atom, lower alkyl, lower cycloalkyl, monocyclic aryl, monocyclic aryl(lower)alkyl or monocyclic aroyl(lower)alkyl, Rb is single bond or lower alkylene, Rc is lower alkyl which is unsubstituted or substituted with halogen, lower cycloalkyl which is unsubstituted or substituted with lower alkyl, monocyclic aryl which is unsubstituted or substituted with halogen or halo(lower)alkyl, or monocyclic aryloxy which is unsubstituted or substituted with halogen or halo(lower)alkyl, or a pharmaceutically acceptable salt when Ra is hydrogen atom.
Description
The present invention relates to a method for the treatment of cataracts which comprises administering a 15-ketoprostaglandin compound to a subject.
Prostaglandins (hereinafter, prostaglandins are referred to as PGs) are members of a class of organic carboxylic acids that are contained in human and most other mammalian tissues or organs and that exhibit a wide range of physiological activities. Naturally occurring PGs possess as a common structural feature the prostanoic acid skeleton:
7 5 3 1 (~-chain) ~, \~ ,GOOH
6 ~ ~7 I O ~ I L 1 6 1 8 2 0 (A) ~ ~ 3 l3 l5 17 19 (~-chain) Some synthetic analogues have somewhat modified skeletons.
The primary PGs are classified based on the structural feature of the five-membered cycle moiety into PGAs, PGBs, PGCs, PGDs, PGEs, PGFs, PGGs, PGHs and PGJs, and also on the presence or absence of unsaturation and oxidation in the chain moiety as:
Subscript 1 - - - 13,14-unsaturated-15-OH
Subscript 2 - - - 5,6- and 13,14-diunsaturated-15-OH
Subscript 3 - - - 5,6- 13,14- and 17,18-triunsaturated Further, PGFs are sub-classified according to the configuration of the hydroxyl group at position 9 into ~(hydroxy group being in the alpha configuration) and ~(hydroxy group being in the beta configuration).
Naturally occurring PGE1, PGE2and PGE3are known to have vasodilating, hypotensive, gastro-juice reducing, intestine-hyperkinetic, uterine contracting, diuretic, bronchodilating and anti-ulcer activities. Also, PGF,a PGF21 and PGF3lare known to have hypertensive, vasocontracting, intestine-hyperkinetic, uterine contracting, luteo-regressive and bronchocontracting activities.
In addition, some 15-keto (i.e. having an oxo group at position 15 in place of the hydroxy group) prostaglandins and 13,14-dihydro-15-ketoprostaglandins are known as substances naturally produced by enzymatic actions during metabolism of primary PGs (Acta Physiologica Scandinavica, 66, 509, 1966).
Also, 15-ketoprostaglandin F2 has been described as possessing an antipregnant activity.
European Patent Application No. 0,310,305 teaches that 15-keto-PGs can be used as catharitics. However, it has not been reported that 15-ketoprostaglandin compounds have an activity useful in treatment of cataracts.
As a result of extensive studies about the biological properties of 15-ketoprostaglandin compounds, the present inventor has discovered that these compounds are useful as an agent for treating cataracts.
In a first aspect, the present invention provides a method for treatment of cataracts which comprises administering, to a subject in need of such treatment, a 15-ketoprostaglandin compound in an amount effective in treatment of cataracts.
In a second aspect, the present invention provides a use of a 15-ketoprostaglandin compound for the manufacture of a medicament for the treatment of cataracts.
In a third aspect, the present invention provides a pharmaceutical composition for treatment of cataracts comprising a 15-ketoprostaglandin compound in association with a pharmaceutically acceptable carrier, diluent or excipient.
Cataracts are a disorder characterized by an opacity of the crystalline lens of the eye. As used herein, the term "cataracts" includes precataracts which can be described as an increase in the intensity of scattered light in the crystalline lens, coloring of the crystalline lens, hardening of a nucleus of lens, and the like. According to the invention, 15-keto-PG compounds can be used for all kinds of cataracts, particularly in prophylaxis, i.e. prevention or inhibition of onset of cataracts, regardless of cause.
Examples of cataracts include senile cataracts, traumatic cataracts, nutritional cataracts, diabetic cataracts, toxic cataracts, radiation cataracts and the like.
As used herein, the term "treatment" or "treating" refers to any means of control of a disease in a mammal, including preventing the disease, curing the disease, relieving the disease and arresting or relieving the development of the disease.
The term "lS-ketoprostaglandin compounds", referred to as 15-keto-PG compounds, include any prostaglandin derivatives which have an oxo group in place of the hydroxy group at position 15 of the prostanoic acid nucleus irrespective of the presence or absence of the double bond between positions 13 and 14.
Nomenclature of 15-keto-PG compounds herein uses the numbering system of prostanoic acid represented in formula (A) shown above.
While formula (A) shows a basic skeleton having twenty carbon atoms, the 15-keto-PG compounds used in the present invention are not limited to those having the same number of carbon atoms. The carbon atoms in Formula (A) are numbered 2 to 7 on the ~-chain starting from the ~-carbon atom adjacent to the carboxylic carbon atom which is numbered 1, and towards the five-membered ring, 8 to 12 on the said ring starting from the carbon atom on which the ~-chain is attached, and 13 to 20 on the ~ -chain starting from the carbon atom adjacent to the ring. When the number of carbon atoms is decreased in the ~-chain, the number is deleted in order starting from position 2 and when the number of carbon atoms is increased in the ~-chain, compounds are named as substituted derivatives having respective substituents at position 1 in place of a carboxyl group (C-1). Similarly, when the number of carbon atoms is decreased in the ~ -chain, the number is deleted in order starting from position 20 and when the number of carbon atoms is increased in the ~ -chain, compounds are named as substituted derivatives having respective substituents at position 20. Stereochemistry of the compounds is the same as that of above formula (A) unless otherwise specified. Thus, 15-keto-PG compounds having 10 carbon atoms in the ~ -chain is nominated as 15-keto-20-ethyl-PGs.
The above formula expresses a specific configuration which is the most typical one, and in this specification compounds having such a configuration are expressed without any specific reference to it.
In general, PGDs, PGEs and PGFs possess a hydroxyl group on the carbon atom at position 9 and/or 11 but in the present specification the term "15-keto-PG compounds" includes PGs having a group other than a hydroxyl group at position 9 and/or 11. Such PGs are referred to as 9-dehydroxy-9-substituted-PG compounds or 11-dehydroxy-11-substituted-PG
compounds.
As stated above, nomenclature of 15-keto-PG compounds is based upon the prostanoic acid. These compounds, however, can also be named according to the IUPAC naming system. For example, 13,14-dihydro-15-keto-16R,S-fluoro-PGE2 is (Z)-7-{(lR,2R,3R)-3-hydroxy-2-[(4R,S)-fluoro-3-oxo-1-octyl]-5-oxocyclopentyl}-hep-5-enoic acid. 13,14-dihydro-15-keto-20-ethyl-11-dehydroxy-llR-methyl-PGE2 methyl ester is methyl 7-{(lR,2S,3S)-3-methyl-2-~3-oxo-1-decyl]-5-oxocyclopentyl}-hept-5-enoate. 13,14-dihydro-6,15-diketo-19-methyl-PGE2 ethyl ester is ethyl 7-{(lR,2S,3S)-3-hydroxy-2-(7-methyl-3-oxo-1-octyl)-5-oxocyclopentyl}-6-oxo-heptanoate. 13,14-dihydro-15-keto-20-ethyl-PGF2a-isopropyl ester is isopropyl (Z)-7-[(lR,2R,3R,5S)-3,5-dihydroxy-2-{3-oxo-1-decyl}-cyclopentyl]-hept-5-enoate.
13,14-dihydro-15-keto-20-methyl-PGF2~ methyl ester is methyl (Z)-7-[(lR,2R,3R,5S)-3,5-dihydroxy-2-{3-oxo-1-nonyl}-cyclopentyl]-hept-5-enoate.
The 15-keto-PG compounds used in the present invention may be any derivative of the PG insofar as they have an oxo group at position 15 in place of the hydroxy group, and may have a double bond between positions 13 and 14 (15-keto-PG
subscript 1 compounds), two double bonds between positions 13 and 14 as well as positions 5 and 6 (15-keto-PG subscript 2 compounds), or three double bonds between positions 13 and 14, positions 5 and 6 as well as positions 17 and 18 (15-keto-PG
subscript 3 compounds), and may have a single bond between positions 13 and 14 (13,14-dihydro-15-keto-PG compounds).
Typical examples of the compounds used in the present invention are 15-keto-PGA, 15-keto-PGD, 15-keto-PGE, 15-keto-PGF, 13,14-dihydro-15-keto-PGA, 13,14-dihydro-15-keto-PGD, 13,14-dihydro-15-keto-PGE, and 13,14-dihydro-15-keto-PGF, wherein PG is as defined above as well as their substitution products or derivatives.
Examples of substitution products or derivatives include esters of the carboxy group at the alpha chain, pharmaceutic-ally or physiologically acceptable salts, unsaturated derivatives having a double bond or a triple bond between positions 2 and 3 or positions 5 and 6, respectively, substituted derivatives having substituent(s) on carbon atom(s) at position 3, 5, 6, 16, 17, 19 and/or 20 and compounds having lower alkyl or a hydroxy (lower) alkyl group at position 9 and/or 11 in place of the hydroxy group, of the above PGs.
Examples of substituents present in preferred compounds are as follows: Substituents on the carbon atom at position 3, 17 and/or 19 include lower alkyl, for example, C~ 4 alkyl, especially methyl and ethyl. Substituents on the carbon atom at position 16 include lower alkyl e.g. methyl, ethyl, and the like, hydroxy and halogen atom e.g. chlorine, fluorine, aryloxy e.g. trifluoromethylphenoxy, etc. Substituents on the carbon atom at position 17 include halogen atom e.g. chlorine, fluorine, and the like. Substituents on the carbon atom at position 20 include saturated and unsaturated lower alkyl e.g.
C~ 4 alkyl, lower alkoxy e.g. C, 4 alkoxy and lower alkoxy (lower) alkyl e.g. C, 4 alkoxy-C14alkyl. Substituents on the carbon atom at position 5 include halogen atom e.g. chlorine, fluorine and the like. Substituents on the carbon atom at position 6 include oxo group forming carbonyl. Stereo-3 5 chemistry of PGs having hydroxy, lower alkyl or lower (hydroxy) alkyl substituent on the carbon atom at position 9 and/or 11 may be alpha, beta or mixtures thereof.
-~_ 6 2039420 Said derivatives may have an alkoxy, phenoxy or phenylgroup at the end of the omega chain where the chain is shorter than the primary PGs.
Especially preferred compounds are those having a lower alkyl e.g. methyl, ethyl etc., a halogen atom e.g. chloro, fluoro etc. at position 16, those having a halogen atom e.g.
chloro, fluoro etc. at position 17, those having a lower alkyl e.g. methyl, ethyl etc. at position 19, those having a halogen atom e.g. chlorine, fluorine etc. at position 5, those having an oxo group at position 6, those having a lower alkyl, e.g.
methyl, ethyl, and the like at position 20 and those having phenyl or phenoxy which are optionally substituted with halogen or haloalkyl at position 16 in place of the rest of the alkyl chain.
A group of preferred compounds used in the present invention have the formula y ~ R,- A
Z ~ (I) ~ - B - C 0 - R2 wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, Z is hydrogen or halo, A is -CH2OH, -COCH2OH, -COOH or its functional derivative, B is -CH2-CH2, -CH=CH- or -C--C-, R1is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl, R2is saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo-`: ' (lower)alkyl, aryl or aryloxy.
Among the compounds of the above formula, the compounds represented by the following formula are novel and form also part of the present invention.
M
C~2-D-~-(CH2) 2-COO~a E-CO-C-~b-~c L / \
Ql Q2 wherein L and M are hydrogen atom, hydroxy, lower alkyl, hydroxy(lower)alkyl or oxo, provided that at least one of L and M is not hydrogen atom and that the five membered ring may have one or two double bonds, Q1and Q2are hydrogen atom, halogen atom or lower alkyl, D is -CH2-CH2-, -CH=CH-, -C-C- or -CO-CH2-, E is -CH2-CH2- or -CH=CH-, W is -CH2-CH2-CH2-, CH=CH-CH2or -CH2-CH=CH-, Ra is hydrogen atom, lower alkyl, cyclo(lower)alkyl, monocyclic aryl, monocyclic aryl(lower)alkyl or monocyclic aroyl(lower)alkyl, Rb is single bond or lower alkylene, Rc is lower alkyl which is unsubstituted or substituted with halogen, lower cycloalkyl which is unsubstituted or substituted with lower alkyl, monocyclic aryl which is unsubstituted or substituted with halogen or halo-(lower)alkyl, or monocyclic aryloxy which is unsubstituted or substituted with halogen or halo(lower)alkyl, or a pharmaceutically acceptable salt when R1is hydrogen atom.
Since they have a specific profile where they possess only part of the action (e.g. an action treating cataracts) of PGs while lacking the rest of the action, they are useful as selective PGs-like agent.
~~ 8 2039420 In the above formula, the term "unsaturated" in the definitions for R~and R2is intended to include at least one and optionally more than one double bond and/or triple bond isolatedly, separately or serially present between carbon atoms of the main and/or side chains. According to usual nomenclature, unsaturation between two serial positions is represented by denoting the lower number of said two positions, and unsaturation between two distal positions is represented by denoting both of the positions. Preferred unsaturation is a double bond at position 2 and a double or triple bond at position 5.
It is preferred that the group -CH=CH- in D has cis configuration and the group -CH=CH- in E has trans configuration.
lS The term "lower or medium aliphatic hydrocarbon residue"
refers to a straight or branched chain hydrocarbyl group having l to 14 carbon atoms (for a side chain, l to 3 carbon atoms being preferred) and preferably 2 to 8 carbon atoms for R1and 3 to lO carbon atoms for R2.
The term "halo" denotes fluoro, chloro, bromo and iodo.
The term "lower" throughout the specification is intended to include a group having l to 6 carbon atoms unless otherwise specified.
The term "lower alkyl" as a group or a moiety in hydroxy(lower)alkyl, monocyclic aryl(lower)alkyl, monocyclic aroyl(lower)alkyl or halo(lower)alkyl includes saturated and straight or branched chain hydrocarbon radicals containing l to 6, carbon atoms, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.
The term "lower alkylene" refers to the group obtainable by removing a hydrogen atom from the lower alkyl group as defined above and includes e.g. methylene, ethylene, propylene (trimethylene), tetramethylene, 2-methyltetramethylene, pentamethylene, hexamethylene, and the like.
The term "lower alkoxy" refers to the group lower-alkyl-O- wherein "lower" alkyl is as defined above.
The term "halo(lower)alkyl" refers to lower alkyl group as defined above which is substituted with at least one and preferably 1 to 3 halogen atoms as defined above and includes for example, chloromethyl, bromomethyl, fluoromethyl, trifluoromethyl, 1,2-dichloromethyl, 1,2,2-trichloroethyl, chloropropyl, chlorobutyl, chloropentyl, chlorohexyl, and the like.
The term "hydroxy(lower)alkyl" refers to lower alkyl as defined above which is substituted with at least one hydroxy group, e. g. hydroxymethyl, l-hydroxyethyl, 2-hydroxyethyl and lo 1-methyl-1-hydroxyethyl.
The term "lower alkanoyloxy" refers to a group of the formula: RCO-O- wherein RCO- is an acyl group formed by oxidation of a lower alkyl group as defined above, e.g.
acetyl.
The term "cyclo(lower)alkyl refers to a cyclic group formed by cyclization of a lower alkyl group as defined above.
The term "aryl" includes unsubstituted or substituted aromatic carbocyclic or heterocyclic (preferably monocyclic) groups, e.g. phenyl, tolyl, xylyl and thienyl. Examples of substituents are halo and halo(lower)alkyl wherein halo and lower alkyl being as defined above.
The term "aryloxy" refers to a group of the formula: ArO-wherein Ar is aryl as defined above.
The term "monocyclic aryl" includes phenyl unsubstituted or substituted with lower alkyl substituent, for example phenyl, tolyl, xylyl, cumenyl, and the like.
The term "monocyclic aryloxy" refers to a group consisting of monocyclic aryl as defined above and bivalent oxygen -O- combined together, and includes, for example, phenoxy tolyloxy, xylyloxy, cumenyloxy, and the like.
The term "monocyclic aryl(lower)alkyl" refers to a group consisting of monocyclic aryl and lower alkyl, both as defined above, combined together, and includes, for example, benzyl, phenethyl, tolylmethyl, and the like.
The term "monocyclic aroyl(lower)alkyl" refers to a group consisting of monocyclic aroyl such as benzoyl unsubstituted or substituted with lower alkyl substituent and lower alkyl as defined above combined together, and includes phenacyl (benzoylmethyl), toluoylmethyl, xyloylmethyl, and the like.
The term "functional derivative" of carboxy as A, includes salts (preferably pharmaceutically acceptable salts), esters and amides.
Suitable "pharmaceutically acceptable salts" includes conventional non-toxic salts, and may be a salt with an inorganic base, for example an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), ammonium salt, a salt with an organic base, for example, an amine salt (e.g.
methylamine salt, dimethylamine salt, cyclohexylamine salt, benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris(hydroxymethylamino)ethane salt, monomethyl-monoethanol-amine salt, procaine salt, caffeine salt, and the like), a basic amino acid salt (e.g. arginine salt, lysine salt, and the like), tetraalkyl ammonium salt and the like. These salts can be prepared by the conventional process, for example from the corresponding acid and base or by salt interchange.
Examples of the esters are aliphatic esters, for example, lower alkyl ester e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, l-cyclopropylethyl ester, and the like, lower alkenyl ester e.g. vinyl ester, allyl ester, and the like, lower alkynyl ester e.g. ethynyl ester, propynyl ester, and the like, hydroxy(lower) alkyl ester e.g. hydroxyethyl ester, lower alkoxy(lower)alkyl ester e.g. methoxymethyl ester, l-methoxyethyl ester, and the like, and aromatic esters, for example, optionally substituted aryl ester e.g.
phenyl ester, tosyl ester, t-butylphenyl ester, salicyl ester, 3,4-dimethoxyphenyl ester, benzamidophenyl ester and the like, aryl(lower)alkyl ester, e.g. benzyl ester, trityl ester, benzhydryl ester, and the like. Examples of the amides are mono- or di- lower alkyl amides e.g. methylamide, ethylamide, dimethylamide, and the like, arylamide e. g. anilide, toluidide, and lower alkyl- or aryl-sulfonylamide e.g.
A
., methylsulfonylamide, ethylsulfonylamide, tolylsulfonylamide and the like.
Preferred examples of A include -COOH, -COOCH3, -COOCHzCH3~ -COOCH(CH3) 2 and -CONHSO2CH3.
The configuration of the ring and the ~- and/or omega chain in the above formula (I) may be the same as or different from that in the primary PGs. However, the present invention also includes a mixture of a compound having a primary configuration and that of an unprimary configuration.
Examples of the typical compounds of the present invention are 15-keto-PGs, 13,14-dihydro-15-keto-PGs and their e.g. 6-oxo-derivatives, ~2-derivatives, 3R,S-methyl-derivatives, 5R,S-fluoro-derivatives, 5,5-difluoro-derivatives, 16R,S-methyl-derivatives, 16,16-dimethyl-derivatives, 16R,S-fluoro-derivatives, 16,16-difluoro-derivatives, 17S-methyl-derivatives, 17R,S-fluoro-derivatives, 17,17-difluoro-derivatives, l9-methyl-derivatives, 20-methyl-derivatives, 20-ethyl-derivatives, l9-desmethyl-derivatives, 2-decarboxy-2-carboxyalkyl derivatives and 16-desbutyl-16-phenoxy derivatives.
When 15-keto-PG compounds of the present invention have a saturated bond between positions 13 and 14, these compounds may be in the keto-hemiacetal equilibrium by forming a hemiacetal between hydroxy group at position 11 and ketone at position 15.
The proportion of both tautomeric isomers, when present, varies depending on the structure of the rest of the molecule or kind of any substituent present and, sometimes, one isomer may predominantly be present in comparison with the other.
However, in this invention, it is to be appreciated that the compounds used in the invention include both isomers.
Further, while the compounds used in the invention may be represented by a structure or name based on keto-form regardless of the presence or absence of the isomers, it is to be noted that such structure or name does not intend elimination of the hemiacetal type of compounds.
In the present invention, any of the individual tautomeric isomers, a mixture thereof, or optical isomers, a mixture thereof, a racemic mixture, and other isomers such as steric isomers can be used in the same purpose.
Some of the compounds used in the present invention may be prepared by the method disclosed in Japanese patent publications (une~m;ned) No. A-52753/1989, A-104040/1989, A-151519/1989.
Alternatively, these compounds may be prepared by a process analogous to that described herein or to known processes.
A practical preparation of the 15-keto compounds involves the following steps; referring to the Synthetic Charts I to III, reaction of the aldehyde (2) prepared by the Collins oxidation of commercially available (-)-Corey lactone (1) with dimethyl (2-oxoheptyl)phosphate anion to give a,~-unsaturated ketone (3), reduction of the ~,~-unsaturated ketone (3) to the corresponding saturated ketone (4), protection of the carbonyl group of the ketone (4) with a diol to the corresponding ketal (5), and deprotection of the p-phenylbenzoyl group to give the corresponding alcohol (6) followed by protection of the newly derived hydroxy group with dihydropyrane to give the corresponding tetrahydropyranyl ether (7). According to the above process, a precursor of PGEs wherein the ~ -chain is a 13,14-dihydro-15-keto-alkyl group iS prepared.
Using the above tetrahydropyranyl ether (7), 6-keto-PGE1s (15) of which a group constituted with carbon atoms at positions 5, 6 and 7 is -5CHz-6C(O)-7CH2-, may be prepared in the following steps; reduction of the tetrahydropyranyl ether (7) with, for example, diisobutyl aluminum hydride to give the corresponding lactol (8), reaction of the lactol (8), with the ylide generated from (4-carboxybutyl)triphenyl phosphonium bromide followed by esterification (10), cyclization between the 5,6-double bond and the hydroxyl group at position 9 with NBS or iodine to give the halogenated compound (11), dehydrohalogenation of the compound (11) with, for example, DBU to give the 6-keto compound (13) followed by Jones oxidation and removal of the protecting groups.
Furthermore, PGEzs (19) of which a group constituted with carbon atoms at positions 5, 6 and 7 is -~H2-C6H=C5H- may be prepared in the following steps; as shown in the Synthetic Chart II, reduction of the above tetrahydropyranyl ether (7) to give the lactol (8), reaction of the resultant lactol (8) with the ylid derived from (4-carboxybutyl-)triphenyl phosphonium bromide to give the carboxylic acid (16) followed by esterification to give ester (17), Jones oxidation of the esters (17) to give the compound (18), and removal of the protecting groups.
Using the above tetrahydropyranyl ether (7) as the starting material, the compound having -~H2- g2-5CH2- may be prepared by using the same process as that for preparing PGE2having -CH2CH=CH- and subjecting the resultant compound (18) to catalytic reduction to reduce the double bond between the positions 5 and 6 followed by removal of the protective groups.
Synthesis of 5,6-dehydro-PGE2s having =~H2-=-5C- may be carried out by capturing a copper enolate formed by 1,4-addition of a monoalkylcopper complex or a dialkylcopper complex of the following formulae:
CU~ >~G Cu~/G
O O O O
I I , I I /~
wherein G is alkyl, to 4R-T-butyldimethylsilyloxy-2-cyclopenten-1-one with 6-alkoxycarbonyl-l-iodo-2-hexyne or the derivatives.
The 11-~ type PGEs can be prepared according to the Synthetic Chart III.
PGE derivatives having a methyl group at position 11 in place of hydroxy can be prepared by reacting a dimethyl copper complex with PGA-type compound obtained by subjecting 9-hydroxy-11-tosylate to the Jones oxidation. Alternatively, they can be prepared by protecting the carbonyl of saturated ketone (4) produced by reducing unsaturated ketone (3), eliminating p-phenylbenzoyl and tosylating the produced alcohol, treating with DBU to form a lactol, introducing the alpha-chain by Wittig reaction, oxidizing the alcohol at position 9 to give a PGA-type compound, and reacting the product with dimethyl copper complex in order to introduce a methyl group into position 11 to give an ll-methyl-PGE-type compound, which on reduction with e.g. sodium borohydride, gives an 11-methyl-PGF-type compound. An ll-hydroxymethyl-PGE-type compound, is obtained by a benzophenone-sensitized photoaddition of methanol of PGA-type compound, which is reduced with, e.g. sodium borohydride, to give an 11-hydroxymethyl-PGF-type compound. The 16-mono- or 16,16-di-halo type PGEs can be prepared according to the synthetic chart IV. The synthetic route for the compounds used in the present invention is not limited to that described above one and may vary using different protecting, reducing and/or oxidizating methods.
Furthermore, the novel compounds of the formula II may be prepared by processes shown in the following Synthetic Charts V to XIII, wherein P1, P2, P3, P4, P5, P6 7 protective groups and Q1, Q2~ Rb and Rc are the same as defined above.
Referring to Synthetic Chart V, the compound (41) (for example, a compound wherein Q1and Q2are hydrogen is the compound 8 described in Synthetic Chart I on page 37 of JP-A-52753/1989) is reacted with a ylid produced from (6-carboxyhexyl)triphenylphosphonium bromide to form the compound (42), which is esterified to give the compound (43), which, on removal of the protective groups, can give the compound (44).
Also, referring to Synthetics Chart VI, the above compound (43) is oxidized by Jones oxidation to form the compound (45), ~`
-which can then form the compound (46) by removal of the protective groups. The compounds wherein W is -CH=CH-CH2- or -CH2-CH=CH- can be prepared by reacting the compound ( 41) with a ylid produced from (6-carboxy-2-hexenyl)triphenylphosphonium bromide or (6-carboxy-3-hexenyl)triphenylphosphonium bromide, respectively, and treating the formed compound in a manner similar to that above.
In another example, referring to Synthetic Chart VII, the compound (48), obtained by deprotecting the compound (47) which is commercially available, is oxidized by Swern oxidation to give the aldehyde (49), which is reacted with 2-oxoheptyl phosphonate (for example, 3,3-dihalogenated derivative) to give the compound (50). Catalytic reduction of it gives the compound (51), the ketone moiety of which is reduced by sodium borohydride to form the compound (52). This is further reduced by diisobutylaluminum hydride to give the lactol (53). On reaction with carboxyhexylphosphonium bromide, it gives the compound (54), which is esterified to the compound (55), oxidized to the compound (56) and deprotected to the compound (46). If desired, this can be hydrolyzed to the free acid ( 57). Also, in the Synthetic Chart VIII, the above compound (55) can be catalytically hydrogenated to form the compound (58), which is oxidized by Swern oxidation to give the compound ( 59) and then deprotected to form the desired compound (60).
In the above process, when the reduction in the step from the compound ( 50) to the compound (41) is omitted, a compound wherein Z is -CH=CH- is obtained.
Further, when the compounds of the formula (I) wherein L
is other than OH (for example, lower alkyl) are desired, the lactone moiety in the compound obtained by removing the protective group at position 11 and introducing a protective group in position 15 of the compound (52) is reduced to lactol and then an ~-chain is introduced to the product by Wittig reaction. Then the hydroxy group at position 11 is protected by a lower alkane- or monocyclic aryl-sulfonate group and the product is subjected to oxidation (for example, Jones) to give .~, a 10-en-9-one compound, which is reacted with lower alkyl lithium to form a 11-lower alkyl compound. Compounds of PGD-type can be obtained by oxidizing the 11-deprotected compounds. Compounds of PGA-type can be obtained from the 10-en-9-one compounds. In addition, as shown in Synthetic Chart IX, 6-keto compounds can be obtained by reacting the compound (43) with N-bromosuccinimide or iodine to form the compound (61), followed by treatment with DBU. The 5,6-dehydro (i.e.
acetylenic) compounds can be prepared, according to Synthetic Chart X, by reacting the copper enolate, formed by reacting the compound (63) with a copper complex, with 8-alkoxycarbonyl-1-iodo-2-octyne. Saturated ~-chain introducing agent are prepared as shown in Synthetic Chart XI.
In a further example, according to Synthetic Chart XII, the hydroxy group at position 15 of the compound (52) is protected (for example, by silyl protective group) to form the compound (65) and lactone moiety of which is reduced to lactol giving the compound (66), which is then reacted with an ~-chain introducing agent (for example, a ylid produced from (6-carboxyhexyl)triphenyl phosphonium bromide) to give thecompound (67). Then the carboxy group is protected to form the compound (68) and the hydroxy group at position 9 is protected to form the compound (69). The protective group at position 15 is removed to give the compound (70), which is oxidized to the compound (71). Deprotection at positions 9 and 11 gives the desired compound (72).
Further, as shown in Synthetic Chart XIII, the compound (54) obtained as in Synthetic Chart VII is protected with a protective group removable by catalytic hydrogenation (for example, benzyl) to form the compound (55), which is oxidized at position 9 and deprotected at position 11 to give the compound (46). Catalytic hydrogenation of this compound gives the desired compound (73).
Corresponding other PG compounds can be produced analogously.
,, - 17- o 2039420 "~ ô
0111 11110 ~
~ ^ o ~"~
~t~ttlo ~ ~ ~
- o~ ~ 3 , ~
\o~ 1111 ~
o~""~, ~ Xo~ ~>
dll Illlo C ~
~-o r~
0~ olll11110 ~ o~< ~ ~
~ o o U~
o~
~
o(llOl~llo o V~
~o tll~1t~10 O
~ ~
.~ ~
t" . .
~, - ly C=:
o ~o oi~ o ~
~
~ Itl~-~
h ~ ~<~
o~ o-G_~' e) 0~;",~ ~_ U~
~`
:~,.
J ~
~,~ ~ - /o~
o ] ~ o ~ '~ _ ~ "~( - o ~o ~ ~
-Synthetic Chart rv 2 0 3 9 4 2 0 o o o ,o~ ,o~ ,o~
Q OSiR3 ~ OH Q CHO
THPO THPO THPO
(28) (29) (30) O O
,0~ ,0~
THPO O THPO O
(31) (32) OH
0~0 ' ,0 r ~
THPO ~ THPO
OH OH
(33) (34) HO
~ ~ ^~==-'^`-~ ~ COOH
"~
THPO
OH
(35) HO
, ~~
THPO
OH
(36) o ~ ~ F F COOR
,~
THPO o (37) o ~r ~\ COOR
F F
.:
HO
(38) o ~ ~ COOR
HO o (39) \~ ~ COOH
~ FF
"~
HO o (40) Synthetic Chart V 2 0 3 9 4 2 0 OH
,0~
r Ql Q2 ~<Rb--Rc P~O O O
P2 (41) OH
COOH
Ql Q2 >
~Rb--Rc P10 o O
P2 (42) OH
~\~~` COOP3 - <~ Ql Q2 -~Rb-Rc P,O O O
P2 (43) OH
~~~ COOP3 ~r Ql Q2 ~ Rb--Rc HO
(44) -Synthetic Chart VI
p O Rb-Rc O O
P2 (45) ~ ~COOP3 HO\~>< Rb--Rc o (46) - 25 ~ 2039420 Synthetic Chart V~
O O O
~ Op 4 OH ~ CHO
P10 P10 PlO
(47) (48) (49) O'- O
~)"' QIQ2 > ~ QIQ2 Pl ~ Rb-Rc P O ~ Rb-Rc (50) (51) O OH
,0~ ' ,0~
~ Q~ Q2 > Q QI Q2 ~
Rb-Rc p, OH OH
(52) (53) HO
~ 4 4 COOH
PlO ~ Rb-~c OH
(54) ^`-=="-`-'^`-'" COOP3 ~" QI Q2 P,0 ~ Rb-Rc OH
(55) ~-o P l (~o Rb -Rc (56) (46) ~ ~COOH
> ~ ~ Ql Q2 H~o <Rb-Rc (57) Synthetic Chart Vll (55)~ <~ QIQ2 PIO~><Rb--Rc OH
(58) > ~"' QIQ2 p o~>~Rb--Rc - (59) - ~ ~ ~ Ql Q2 ~><Rb--Rc HO O
(60) .~
~ 28- 2039420 Synthetic Chart lX
Br ~ ~ ~ ,COOP3 (43) ~ <> Ql Q2 P o ~'>~ Rb - Rc P2 (61) OH :~~~/~ COOP3 "' O
\~< Rb--Rc P~O O O
P2 (62) A
t~ -- 29 ~ ~03~420 Synthetic Chart X
Ql Q2 i) Cu ~ Rb - Rc O O O
\ P2 (a) /n(n=1,2) >
PsO ~ =' ~ ~ ~ ' ~ COOP3 (63) (b) > ~ I COOP3 Rb - Rc P 2 (64) Synthetic Chart ~1 Br~ '~ " CN ~ Br-'~~ " COOH
(c) (d) ~~~~ ~ COOH
Br P Ph3 (e) Synthetic Chart Xl[ 2 0 3 9 4 2 0 ,o~
(52) ~ <~ Ql Q2 >
P I O~><Rb--Rc - (65) OH
,0~
<~ Q~ Q2 P I O~XRb-Rc (66) HO
<> ~) Q COOH
p I o~XRb -Rc >
(67) HO
~ --COOP3 ~" Ql Q2 P I o ~ ~Rb-Rc (68) F~`
~----COOP3 P I O~><Rb-Rc (69) p o ~Rb-Rc OH
(70) ~----~COOP3 p, o o~Rb-Rc (71) ~ ~COOP3 HO--I~<Rb-Rc (72) ~' ~ 31a ~
Synthetic Chart ~II 2 0 3 9 4 2 0 (54) ~ (55) ~ (56) > (46)~
~COOH
- - ~ Ql Q2 HO ~Rb-Rc (73) :,~
32 ~0 ~420 Since the compounds used in the present invention have an activity useful for preventing or curing cataracts, these can be used for preparing a medicament for treating cataracts.
Such activities can be measured by the standard methods such as galactose-induced cataract of rats.
The compounds used in the present invention may be used as a medicine for animals and human beings and usually applied systemically or locally by such methods as ophthalmic administration, oral administration, intravenous injection (including instillation), subcutaneous injection, suppository and the like. While the dosage will vary depending on the particular animal or human patient, age, body weight, symptom to be treated, desired therapeutic effect, administration route, term of treatment and the like, satisfactory effects will be obtained with the dosage of 0.01 - 100 ~g/eye administered locally or 0.001 - 500 mg/kg administered systemically in 2 to 4 divided doses a day or as a sustained form.
The ophthalmic composition used according to the invention includes ophthalmic solution, ophthalmic ointment and the like. The ophthalmic solution can be prepared by dissolving an active ingredient in a sterile aqueous solution such as a physiological saline or a buffered solution, or as a combination of a solid and a solution for dissolving said solid to make a ready-to-use preparation. The ophthalmic ointment can be prepared by mixing an active ingredient with an ointment base.
The solid composition for oral administration used according to the invention includes tablets, troches, buccals, capsules, pills, powders, granules and the like. The solid composition contains one or more active substances in admixture with at least an inactive diluent, e.g. lactose, mannitol, glucose, hydrocypropyl cellulose, fine crystalline cellulose, starch, polyvinyl pyrolidone, and magnesium aluminate metasilicate. The composition may contain additives, in addition to the inactive diluent, for example, lubricants e.g., magnesium stearate, a disintegrator e.g.
~' cellulose calcium gluconates, stabilizers e.g. ~ - or r-cyclodextrins, etherated cyclodextrins (e.g. dimethyl-~-, dimethyl-~-, trimethyl-~-, or hydroxypropyl-~-cyclodextrins), branched cyclodextrins (e. g. glucosyl- or maltosyl-cyclodextrins), formyl cyclodextrins, sulfur-containing cyclodextrins, misoprotols or phospholipids. Such cyclodextrins may increase the stability of the compounds by forming an inclusion compounds. The stability may be often increased by forming lyposome with phospholipids. Tablets and pills may be coated with an enteric or gastroenteric film e.g.
white sugar, gelatin, hydroxypropylcellulose, hydroxy-propylmethylcellulose phthalates and the like, if necessary, and furthermore they may be covered with two or more layers. Additionally, the composition may be in the form of capsules made of substance easily absorbed e.g. gelatin.
The composition may be in the form of buccals, when an immediate effect is desired. For this purpose, base e.g.
glycerine, lactose may be used.
Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like and contain a commonly used inactive diluent e.g. purified water or ethyl alcohol. The composition may contain additives e.g. wetting agents, suspending agents, sweeteners, flavors, perfumes and preservatives.
The composition of the present invention may be in the form of sprays which may contain one or more active ingredients and which can be prepared according to well known methods.
An injection of this invention for non-oral administration includes sterile aqueous or nonaqueous solutions, suspensions, and emulsions. Diluents for the aqueous solution or suspension include, for example, distilled water for injection, physiological saline and Ringer's solution. Diluents for the nonaqueous solution and suspension include, for example, propylene glycol, polyethylene glycol, vegetable oils e.g. olive oil, alcohols, e.g. ethanol and A
polysorbates. The composition may contain other additives, e.g. preservatives, wetting agents, emulsifying agents, dispersing agents and the like. These are sterilized by filtration through, e.g. a bacteria-retaining filter, compounding with a sterilizer, gas sterilization or radiation sterilization. These can be prepared by producing a sterilized water or a sterilized solvent for injection before use.
Another formulation according to the present invention is a rectal or vaginal suppository. This can be prepared by mixing at least one active compound according to the invention with a suppository base e.g. cacao butter and optionally containing nonionic surfactant for improving absorption.
A more complete understanding of the present invention can be obtained by reference to the following Preparation Examples, Formulation Examples and Test Examples which are provided herein for purpose of illustration only and are not intended to limit the scope of the invention.
Preparation Example I
Preparation of 16,16-difluoro-13,14-dihydro-15-keto-PGE1methyl ester (39) 1-1) Preparation of (lS,5R,6R,7R)-6-hydroxymethyl-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]octan-3-one (29) To a solution of (-) commercial Corey lactone (THP-form 37.9g) in tetrahydrofuran was added a solution (1.0 M, 300 ml) of tetrabutylammonium fluoride in tetrahydrofuran and the resultant mixture was stirred at room temperature for 3 hours.
The resultant mixture was then concentrated under reduced pressure and the residue subjected to column chromatography to give the titled compound (29).
Yield: 21.70g (82.8%).
1-2) Preparation of (lS,5R,6R,7R)-6-((E)-4,4-difluoro-5-oxo-2-octenyl}-7-tetrahydropyranyloxy-2-oxabicyclo [3.3.0]octan-3-one (31) A solution (2.0 M, 45.5 ml) of oxalyl chloride in methylene chloride was diluted with methylene chloride under ~' -35 2 ~3 ~420 an argon atmosphere at -78C. To this solution was added dropwise dimethylsulfoxide (12.9 ml) and the resultant mixture stirred for 10 minutes. A solution (lS, 5R, 6R, 7R)-6-hydroxymethyl-7-tetrahydropyranyloxy-2-oxabicylot3.3.0]octan-3-one (29) (11.65 g) in methylene chloride was added dropwise and the mixture was stirred for 30 minutes. Then triethylamine (56 ml) was added dropwise and stirring was continued for a further 1 hour. The resultant mixture was worked up with the conventional procedure to give the crude aldehyde product (30).
To a solution of thallium ethoxide (3.26 ml) in methylene chloride was added under an argon atmosphere dimethyl 3,3-difluoro-2-oxoheptylphosphonate (11.9 g) and the resultant mixture was stirred for 1 hour. After cooling the solution to 0C, a solution of the aldehyde (30) obtained above in methylene chloride was added dropwise to said solution and the mixture was stirred at room temperature for 14 hours. The reaction mixture was treated with acetic acid, celite and a saturated aqueous potassium iodide solution and filtered. The filtrate was worked up with the conventional procedure and the crude product was subjected to column chromatography to give the titled compound (31).
Yield: 7.787 g (44.3 %).
1-3) Preparation of (lS,5R,6R,7R)-6-(4,4-difluoro-5-oxo-octyl)-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]octan-3-one (32) To a solution of (lS,5R,6R,7R)-6-~(E)-4,4-difluoro-5-oxo-2-octenyl}-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]octan-3-one (31) (5.57 g) in ethyl acetate was added 5% Pd/C
(catalytic amount) and the resultant mixture was shaken under a hydrogen atmosphere at room temperature for 7 hours. The resultant mixture was filtered and the filtrate was concen-trated under reduced pressure to give the titled compound (32) as a crude product. Yield: 5.48 g (97.8%).
1-4) Preparation of (lS,5R,6R,7R)-6-{4,4-difluoro-5(RS)-hydroxyoctyl~-7-tetrahydropyranyloxy-2-oxabicyclo-[3.3.0]-octan-3-one (33).
~'--To a solution of (lS,5R,6R,7R)-6-(4,4-difluoro-5-oxooctyl)-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]octan-3-one (32) (5.48 g) in methanol was added sodium borohydride (0.800 g) at 0C and the resultant mixture was stirred for lO
minutes. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to column chromatography to give the titled compound (33). Yield: 5.46 g (99.5%).
1-5) Preparation of 16,16-difluoro-13,14-dihydro-11-0-tetra-hydropyranyl-PGF2~ methyl ester (36) A solution of (lS,5R,6R,7R)-6-{4,4-dihydro-5(RS)-hydroxyoctyl}-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]-octan-3-one (33) (2.579 g) in toluene was cooled to -78C under an argon atmosphere. To this solution was added dropwise a solution (1.5 M, 9.6 ml) of diisobutylaluminum hydride in toluene and stirred for 30 minutes. The resultant mixture was worked up with methanol and a saturated aqueous Rochelle salt solution. Then the resultant solution was worked up with the conventional procedure to give the crude lactol product (34).
To a suspension of 4-carboxybutyl triphenyl phosphine bromide (11.72 g) in tetrahydrofuran was added dropwise under an argon atmosphere a solution (1.0 M, 52.84 ml) of potassium tert-butoxide in tetrahydrofuran and the resultant mixture was stirred for 20 minutes. The solution was cooled to 0C and combined with a solution of lactol (34) in tetrahydrofuran.
The resultant mixture was stirred at room temperature for 15 hours and then worked up with the conventional procedure to give the crude carboxylic acid product (35).
To a solution of the carboxylic acid (35) in acetonitrile was added under an argon atmosphere 1,8-diazabicyclo[5.4.0]
undec-7-ene (DBU) (4.0 ml) and methyl iodide (1.7 ml) and the resultant solution was stirred at 60C for 30 hours. The resultant solution was worked up with the conventional procedure and the residue was subjected to column chromatography to give the titled compound (36).
Yield: 2.737 g (84.5%).
~,' .
1-6) Preparation of 16,16-difluoro-13,14-dihydro-15-keto-11-0-tetrahydropyranyl-PGE2methyl ester (37) To a solution of Collins reagent, prepared from chromic anhydride (16.18 g) and pyridine (26.2 ml) in the conventional process, in methylene chloride was added a solution of 16,16-difluoro-13,14-dihydro-ll-O-tetrahydropyranyl-PGF2amethyl ester (36) (2.646 g) in methylene chloride under an argon atmosphere at -20C. The resultant mixture was stirred at the same temperature for 2 hours and at -5C for 9 hours. The solution was treated with ether and sodium hydrogen sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was subjected to column chroma-tography to give the titled compound (37). Yield: 1.890 g (64.4%).
1-7) Preparation of 16,16-difluoro-13,14-dihydro-15-keto PGE2 methyl ester (38).
Into a mixed solvent of acetic acid : water : tetra-hydrofuran (3:1:1) was dissolved 16,16-difluoro-13,14-dihydro-15-keto-ll-0-tetrahydroxypyranyl-PGE2methyl ester (37) (2.809 g) and the resultant solution was stirred at 60C for 5 hours.
The resultant mixture was concentrated under reduced pressure and the residue was subjected to chromatography to give the titled compound (38).
Yield: 1.755 g (75.5%).
1-8) Preparation of 16,16-difluoro-13,14-dihydro-15-keto PGE1methyl ester (39) To a solution of 16,16-difluoro-13,14-dihydro-15-keto-PGE2 methyl ester (38) (1.755 g) in ethyl acetate was added Pd/C
(catalytic amount) and the mixture was shaken under a hydrogen atmosphere at room temperature for 6 hours. The resultant mixture was filtered. The filtrate was concentrated and the residue was subjected to column chromatography to give the titled compound (39). Yield: 1.655 g (93.8%).
1H NMR(CDCl3) ~0.87(3H,t,J=7Hz), 1.15-2.05(23H,m), 2.11-2.30(3H,m), 2.50(lH,dd,J=7.5 and 17Hz), 3.10-3.20 (lH,br), 3.71(3H,s), 4.05-4.20(lH,m) MS(DI-EI) m/z 404(M), 355 (~-H20-CH30), 297(M'-C5H9F2) ~:' .. --Preparation Example 2 Preparation of 16,16-difluoro-13,14-dihydro-15 keto-PGE1 (40) 2-1) Preparation of (15RS)-16,16-difluoro-13,14-dihydro ll-O-tetrahydropyranyl-PGF2abenzyl ester (36) To a solution of 16,16-difluoro-13,14-dihydro-11-O-tetrahydropyranyl-PGF2Q(35) (2.33 g) in dichloromethane (300 ml) were added DBU (2.1 ml) and benzyl bromide (2.2 ml) and the resultant mixture was stirred at room temperature for 1.5 hours. The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the titled compound (36).
Yield: 2.522 g (96.1%).
2-2) Preparation of 16,16,difluoro-13,14-dihydro-15-keto-11-0-tetrahydropyranyl-PGE2benzyl ester (37) Collins reagent was prepared by using chromic anhydride (13.5 g) and pyridine (21.8 ml) in dichloromethane (300 ml), and to this were added Celite (40 g) and (15RS)-16,16-difluoro-13,14-dihydro-11-0-tetrahydropyranyl-PGFz~ benzyl ester (36) (2.550 g). The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the titled compound (37). Yield: 1.991 g (78.6%).
2-3) Preparation of 16,16-difluoro-13,14-dihydro-15-keto-PGE2benzyl ester (38) Into a mixed solvent of acetic acid:THF:water (3:1:1, 50 ml) was dissolved 16,16-difluoro-13,14-dihydro-15-keto-11-O-tetrahydropyranyl-PGE2benzyl ester (37) (1.550 g) and the solution was kept at 50C for 4 hours. The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the titled compound (38). Yield: 1.225g (92.9%).
2-4) Preparation of 16,16-difluoro-13,14-dihydro-15-keto-PGE
(40) To a solution of 16,16-difluoro-13,14-dihydro-15-keto-PGE~
benzyl ester (38) (0.844 g) in ethyl acetate (30 ml) was added 5% Pd/C and the mixture was shaken under a hydrogen ~.
, -- 2~39420 atmosphere. The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the titled compound (43).
Yield: 0.404 g.
1H NMR(CDCl3) ~0.94 (t,3H,J=7.5 Hz), 1.20-2.70 (m,26H), 4.19 (m,lH), 4.80 (br,2H).
MS(DI-EI) m/z 390(M'), 372(M+-H20), 354(M'-2H20).
PreParation Example 3 Preparation of 20-ethyl-2-decarboxy-2-(2-carboxy-ethyl)-13,14-dihydro-15-keto-PGF2a isopropyl ester (44) [IUPAC
nomenclature: isopropyl (Z)-9-(lR)-[(2R,3R,5S)-3,5-dihydroxy-2- (3-oxodecyl)cyclopentyl]-7-nonenoate].
3-1) Preparation of (Z)-9-(lR)-[(2R,3R,5S)-2-(3,3-ethylene-dioxydecyl)-5-hydroxy-3-(tetrahydropyranyloxy)cyclopentyl]-7-nonenoic acid (42) Sodium hydride (60%, 0.422g) was washed with hexane under an argon atmosphere. To this was added dimethyl sulfoxide (DMSO, lOml) and the resultant mixture was kept at 60C for 3 hours. After cooling to room temperature, the resultant mixture was treated with 6-carboxyhexyltriphenylphosphonium bromide (2.49g), stirred at room temperature for 2 hours, then at 45C for 1 hour, and poured into ice-water. The resultant mixture was worked up with the conventional procedure to give the titled compound (42). Yield: 1.68g.
3-2) Preparation of isopropyl (Z)-9-(lR)-[(2R,3R,5S)-2-(3,3-ethylenedioxydecyl)-5-hydroxy-3-(tetrahydropyranyloxy)-cyclopentyl]-7-nonenoate (43) The compound (42) (1.68g) was esterified in the conventional procedure with 1,8-diazabicyclo[5.4.0]-7-undecene (DBU, 0.78ml) and isopropyl iodide (0.35ml) in acetonitrile (15ml). The residue was subjected to silica gel column chromatography to give the titled compound (43). Yield:
0.908g (88%) 3-3) Preparation of isopropyl (Z)-9-(lR)-[(2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-7-nonenoate (44) The compound (43) (0.305g) was dissolved in a mixed solvent (6ml) consisting of acetic acid, THF and water (2:1:1) ~,-203 942~
and kept at 50C for 14 hours. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chroma-tography to give the titled compound (44). Yield: 0.213g 5 (90%).
Compound (44) [Q1=Q2=H, Rb-Rc=hexyl, P3=isopropyl]
1H NMR(CDC13)~: 0.85 (t,3H,J=6.5Hz), 1.20 (d,6H,J=6Hz), 1.23-2.65 (m,34H), 3.86 (m,lH), 4.16 (m.lH), 4.99 (Hept,lH,J=6Hz), 5.39 (m,2H).
Preparation Example 4 Preparation of 20-ethyl-2-decarboxy-2-(2-carboxy-ethyl-13,14-dihydro-15-keto-PGE2isopropyl ester (46) [IUPAC
nomenclature: isopropyl (Z)-9-(lR)-[(2R,3R)-3-hydroxy-5-oxo-2-(3-oxodecyl)cyclopentyl]-7-nonenoate]
4-1) Preparation of (Z)-9-(lR)-[(2R,3R)-2-(3,3-ethylene-dioxydecyl)-5-oxo-3-(tetrahydropyranyloxy)cyclopentyl]-7-nonenoate (45) Oxalyl chloride (2M, 0.45ml) and DMSO (0.13ml) were added to dichloromethane (5ml) cooled previously to -70C and the resultant mixture was stirred for 15 hours. A solution of isopropyl (Z)-9-(lR)-[(2R,3R,5S)-2-(3,3-ethylenedioxydecyl)-S-hydroxy-(3-tetrahydropyranyloxy)-cyclopentyl]-7-nonenoate (43) (0.35g) in dichloromethane (7ml) was added dropwise to the above solution. After stirring at -55C for 15 minutes, the resultant mixture was treated with triethylamine (0.25ml) and warmed up to 10C over 6 hours. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (45). Yield:
0.311g (89%).
4-2) Preparation of isopropyl (Z)-9-(lR)-[(2R,3R)-3-hydroxy-5-oxo-2-(3-oxodecyl)cyclopentyl]-7-nonenoate (46) The compound (45) (0.311g) was dissolved in a mixed solvent (5ml) consisting of acetic acid, THF and water (2:1:1) and kept at 50C for 3 hours. The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the ,~
41 ' 2039420 titled compound (46). Yield: 0.156g (66%). Compound (46) [Q1=Q2=H, Rb-Rc=hexyl, P3=isopropyl]
H NMR(CDC13)~: 0.86 (t,3H,J=6.5Hz), 1.20 (d,6H,J=6Hz), 1.23-2.75 (m,33H), 4.20 (m,lH), 4.99 (Hept,lH,J=6Hz), 5.15-5.50 (m,2H).
Preparation Example 5 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13, 14-dihydro-16,16-difluoro-15-keto-PGE2(47) tIUPAC
nomenclature: (Z)-9-(lR)-[(2R,3R)-2-(4,4-difluoro-3-oxo-octyl)-3-hydroxy-5-oxopentyl]-7-nonenoic acid]
Preparation of starting compound: (6-carboxy-hexyl) triphenylphosphonium bromide (e).
A mixture of 7-bromoheptanonitrile (c) (lO.Og) and 40%
hydrobromic acid (80ml) was heated under reflux for 6 hours.
The mixture was diluted with water, extracted with ether and then worked up with the conventional procedure to give a crude product. The residue was subjected to silica gel column chromatography to give 7-bromoheptanoic acid (d). Yield:
7.60g (69%) Treatment of 7-bromoheptanoic acid (d) (7.60g) with triphenylphosphine (lO.Og) gave (6-carboxyhexyl)-triphenylphosphonium bromide (e). Yield: 16.0g (93%).
Preparation of the desired compound 5-1) Preparation of (lS,SR,6R,7R)-6-(4,4-difluoro-3-oxo-octenyl)-7-(tetrahydropyranyloxy)-2-oxabicyclo[3.3.0]-octan-3-one (50) The Swern oxidation of (lS,5R,6R,7R)-6-hydroxy-methyl-7-(tetrahydropyranyloxy)-2-oxabicyclo[3.3.0]octan-3-one (48) (27.8g), which was obtained from commercial (lS,5R,6R,7R)-6-(5-butyldimethylsilyloxymethyl)-7-(tetrahydropyranyloxy)-2-oxabicyclo[3.3.0]octan-3-one (47), using oxalyl chloride (2.0M, 109.3ml), DMS0 (31.0ml) and trimethylamine (150ml) in dichloromethane (800ml) gave the compound (49) (P1=tetrahydropyranyl).
The above compound (49) was reacted with dimethyl 3,3-difluoro-2-oxoheptylphosphonate (30.0g) in dichloromethane in the presence of thallium methoxide (8.23ml). The resultant ,~
-mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (50). Yield: 24.4g (58%).
5 5-2) Preparation of (lS,5R,6R,7R)-6-(4,4-difluoro-3-oxo-octyl)-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]octan-3-one (51) The compound (50) (12.7g) was catalytically hydrogenated over 5% palladium on carbon (catalytic amount) in ethyl acetate (300ml) under a hydrogen atmosphere to give the titled compound (51). Yield: 12.5g (99%).
5-3) Preparation of (lS,5R,6R,7R)-6-[4,4-difluoro-3(R,S)-hydroxyoctyl]-7-tetrahydroxypyranyloxy-2-oxabicyclo-[3.3.0]octan-3-one (52) The compound (51) (12.6g) was reduced with sodium borohydride (1.25g) in methanol (400ml) at 0 C to give the titled compound (52). Yield: 12.lg (95.5%).
5-4) Preparation of (lS,5R,6R,7R)-6-[4,4-difluoro-3(R,S)-hydroxyoctyl]-7-tetrahydroxypyranyloxy-2-oxabicyclo-[3.3.0]octan-3(R,S)-ol (53) The compound (52) (12.lg) was reduced with diisobutylaluminum hydride (1.5M, 65.lml) in toluene (500ml) at -78 C and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (53).
Yield: ll.lg (91%).
5-5) Preparation of phenacyl (Z)-9-(lR)-[(2R,3R,5S)-2-~4,4-difluoro-(3RS)-hydroxyoctyl)-5-hydroxy-3-(tetrahydro-pyranyloxy)cyclopentyl]-7-nonenoate (55) Sodium hydride (60%, 1.63g) was washed with pentane. To this was added DMS0 (40ml) and the resultant mixture was kept at 65-70C for 1.5 hours. After cooling to the room temperature, carboxyhexylphosphonium bromide (e) (9.61g) was added to the mixture to form a ylid. A solution of the compound (53) in DMS0 (15ml) was added dropwise to the ylid in solution and the mixture was kept overnight at room temperature. The resultant mixture was worked up with conventional procedure to give the compound (54).
~.
-Yield: 3.18g (crude).
The compound (54) (0.795g), phenacyl bromide (l.Olg) and diisopropylethylamine (0.89ml) were dissolved in acetonitrile (lOml) and the solution was kept at room temperature for 20 minutes and then at 45C for 30 minutes. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silicagel column chromatography to give the titled compound (55).
Yield: 0.604g.
5-6) Preparation of phenacyl (Z)-9-(lR)-[(2R,3R)-2-{4,4-difluoro-3-oxooctyl}-5-oxo-3-(tetrahydropyranyloxy)-cyclopentyl]-7-nonenoate (56) DMSO (0.92ml) was added dropwise to a solution of oxalyl chloride (0.52ml) in dichloromethane (30ml) previously cooled to -78C. The compound (55) (0.609g), dissolved in dichloromethane (15ml), was added to the above solution and the resultant mixture was stirred at -30C to -20C for 1.5 hours. The resultant mixture was treated with triethylamine (1.88ml) and stirred for 30 minutes. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silicagel column chromatography to give the titled compound (56). Yield: 0.514g (85%).
5-7) Preparation of phenacyl (Z)-9-(lR)-[(2R,3R)-2-{4,4-difluoro-3-oxooctyl}-3-hydroxy-5-oxocyclopentyl]-7-nonenoate (46) The compound (56) (0.514g) was dissolved in a mixed solvent (30ml) consisting of acetic acid, THF and water (4:2:1) and the solution was kept overnight at room temperature. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (46). Yield: 0.272g (61%).
Compound (46) [Q1=Q2=F, Rb-Rc=butyl, P3=phenacyl]
1H NMR(CDCl3)~: 0.92 (t,3H,J=7.5Hz), 1.2-2.9 (m,27H), 4.18 (m,lH), 5.4 (m,2H), 7.4-8.0 (m,5H) 5-8) Preparation of (Z)-9-(lR)-[(2R,3R)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]-7-nonenoic acid 57) -A solution of the compound (46) (0.272g) in acetic acid (lOml) was treated with zinc (3.5g) added in portions at room temperature for 2.5 hours. The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the titled compound (57). Yield: 0.177g (81%). Compound (57) [Q1=Q2=F, Rb-Rc=butyl]
H NMR(CDCl3)~: 0.93(t,3H,J=6.5Hz), 1.15-2.95 (m,28H), 4.19 (m,lH), 5.36 (m,lH) PreParation Example 6 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-16,16-difluoro-15-keto-PGE1isopropyl ester [IUPAC
nomenclature: isopropyl 9-(lR)-[(2R,3R)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]nonenoate 6-1) Preparation of isopropyl (Z)-9-(lR)-[(2R,3R,5S)-2-{4,4-difluoro-(3RS)-hydroxyoctyl}-5-hydroxy-3-(tetrahydropyranyloxy)cyclopentyl]-7-nonenoate (55) The compound (54) (0.802g) obtained in Preparation Example 5, DBU (0.76ml) and isopropyl iodide (0.51ml) were dissolved in acetonitrile (15ml) and kept at 50C for 1 hour. Compound (54) (0.492g) was treated in the same way.
The resultant mixture was worked up with the conventional procedure to give the titled compound (55).
Yield (combined): 0.315g.
Prostaglandins (hereinafter, prostaglandins are referred to as PGs) are members of a class of organic carboxylic acids that are contained in human and most other mammalian tissues or organs and that exhibit a wide range of physiological activities. Naturally occurring PGs possess as a common structural feature the prostanoic acid skeleton:
7 5 3 1 (~-chain) ~, \~ ,GOOH
6 ~ ~7 I O ~ I L 1 6 1 8 2 0 (A) ~ ~ 3 l3 l5 17 19 (~-chain) Some synthetic analogues have somewhat modified skeletons.
The primary PGs are classified based on the structural feature of the five-membered cycle moiety into PGAs, PGBs, PGCs, PGDs, PGEs, PGFs, PGGs, PGHs and PGJs, and also on the presence or absence of unsaturation and oxidation in the chain moiety as:
Subscript 1 - - - 13,14-unsaturated-15-OH
Subscript 2 - - - 5,6- and 13,14-diunsaturated-15-OH
Subscript 3 - - - 5,6- 13,14- and 17,18-triunsaturated Further, PGFs are sub-classified according to the configuration of the hydroxyl group at position 9 into ~(hydroxy group being in the alpha configuration) and ~(hydroxy group being in the beta configuration).
Naturally occurring PGE1, PGE2and PGE3are known to have vasodilating, hypotensive, gastro-juice reducing, intestine-hyperkinetic, uterine contracting, diuretic, bronchodilating and anti-ulcer activities. Also, PGF,a PGF21 and PGF3lare known to have hypertensive, vasocontracting, intestine-hyperkinetic, uterine contracting, luteo-regressive and bronchocontracting activities.
In addition, some 15-keto (i.e. having an oxo group at position 15 in place of the hydroxy group) prostaglandins and 13,14-dihydro-15-ketoprostaglandins are known as substances naturally produced by enzymatic actions during metabolism of primary PGs (Acta Physiologica Scandinavica, 66, 509, 1966).
Also, 15-ketoprostaglandin F2 has been described as possessing an antipregnant activity.
European Patent Application No. 0,310,305 teaches that 15-keto-PGs can be used as catharitics. However, it has not been reported that 15-ketoprostaglandin compounds have an activity useful in treatment of cataracts.
As a result of extensive studies about the biological properties of 15-ketoprostaglandin compounds, the present inventor has discovered that these compounds are useful as an agent for treating cataracts.
In a first aspect, the present invention provides a method for treatment of cataracts which comprises administering, to a subject in need of such treatment, a 15-ketoprostaglandin compound in an amount effective in treatment of cataracts.
In a second aspect, the present invention provides a use of a 15-ketoprostaglandin compound for the manufacture of a medicament for the treatment of cataracts.
In a third aspect, the present invention provides a pharmaceutical composition for treatment of cataracts comprising a 15-ketoprostaglandin compound in association with a pharmaceutically acceptable carrier, diluent or excipient.
Cataracts are a disorder characterized by an opacity of the crystalline lens of the eye. As used herein, the term "cataracts" includes precataracts which can be described as an increase in the intensity of scattered light in the crystalline lens, coloring of the crystalline lens, hardening of a nucleus of lens, and the like. According to the invention, 15-keto-PG compounds can be used for all kinds of cataracts, particularly in prophylaxis, i.e. prevention or inhibition of onset of cataracts, regardless of cause.
Examples of cataracts include senile cataracts, traumatic cataracts, nutritional cataracts, diabetic cataracts, toxic cataracts, radiation cataracts and the like.
As used herein, the term "treatment" or "treating" refers to any means of control of a disease in a mammal, including preventing the disease, curing the disease, relieving the disease and arresting or relieving the development of the disease.
The term "lS-ketoprostaglandin compounds", referred to as 15-keto-PG compounds, include any prostaglandin derivatives which have an oxo group in place of the hydroxy group at position 15 of the prostanoic acid nucleus irrespective of the presence or absence of the double bond between positions 13 and 14.
Nomenclature of 15-keto-PG compounds herein uses the numbering system of prostanoic acid represented in formula (A) shown above.
While formula (A) shows a basic skeleton having twenty carbon atoms, the 15-keto-PG compounds used in the present invention are not limited to those having the same number of carbon atoms. The carbon atoms in Formula (A) are numbered 2 to 7 on the ~-chain starting from the ~-carbon atom adjacent to the carboxylic carbon atom which is numbered 1, and towards the five-membered ring, 8 to 12 on the said ring starting from the carbon atom on which the ~-chain is attached, and 13 to 20 on the ~ -chain starting from the carbon atom adjacent to the ring. When the number of carbon atoms is decreased in the ~-chain, the number is deleted in order starting from position 2 and when the number of carbon atoms is increased in the ~-chain, compounds are named as substituted derivatives having respective substituents at position 1 in place of a carboxyl group (C-1). Similarly, when the number of carbon atoms is decreased in the ~ -chain, the number is deleted in order starting from position 20 and when the number of carbon atoms is increased in the ~ -chain, compounds are named as substituted derivatives having respective substituents at position 20. Stereochemistry of the compounds is the same as that of above formula (A) unless otherwise specified. Thus, 15-keto-PG compounds having 10 carbon atoms in the ~ -chain is nominated as 15-keto-20-ethyl-PGs.
The above formula expresses a specific configuration which is the most typical one, and in this specification compounds having such a configuration are expressed without any specific reference to it.
In general, PGDs, PGEs and PGFs possess a hydroxyl group on the carbon atom at position 9 and/or 11 but in the present specification the term "15-keto-PG compounds" includes PGs having a group other than a hydroxyl group at position 9 and/or 11. Such PGs are referred to as 9-dehydroxy-9-substituted-PG compounds or 11-dehydroxy-11-substituted-PG
compounds.
As stated above, nomenclature of 15-keto-PG compounds is based upon the prostanoic acid. These compounds, however, can also be named according to the IUPAC naming system. For example, 13,14-dihydro-15-keto-16R,S-fluoro-PGE2 is (Z)-7-{(lR,2R,3R)-3-hydroxy-2-[(4R,S)-fluoro-3-oxo-1-octyl]-5-oxocyclopentyl}-hep-5-enoic acid. 13,14-dihydro-15-keto-20-ethyl-11-dehydroxy-llR-methyl-PGE2 methyl ester is methyl 7-{(lR,2S,3S)-3-methyl-2-~3-oxo-1-decyl]-5-oxocyclopentyl}-hept-5-enoate. 13,14-dihydro-6,15-diketo-19-methyl-PGE2 ethyl ester is ethyl 7-{(lR,2S,3S)-3-hydroxy-2-(7-methyl-3-oxo-1-octyl)-5-oxocyclopentyl}-6-oxo-heptanoate. 13,14-dihydro-15-keto-20-ethyl-PGF2a-isopropyl ester is isopropyl (Z)-7-[(lR,2R,3R,5S)-3,5-dihydroxy-2-{3-oxo-1-decyl}-cyclopentyl]-hept-5-enoate.
13,14-dihydro-15-keto-20-methyl-PGF2~ methyl ester is methyl (Z)-7-[(lR,2R,3R,5S)-3,5-dihydroxy-2-{3-oxo-1-nonyl}-cyclopentyl]-hept-5-enoate.
The 15-keto-PG compounds used in the present invention may be any derivative of the PG insofar as they have an oxo group at position 15 in place of the hydroxy group, and may have a double bond between positions 13 and 14 (15-keto-PG
subscript 1 compounds), two double bonds between positions 13 and 14 as well as positions 5 and 6 (15-keto-PG subscript 2 compounds), or three double bonds between positions 13 and 14, positions 5 and 6 as well as positions 17 and 18 (15-keto-PG
subscript 3 compounds), and may have a single bond between positions 13 and 14 (13,14-dihydro-15-keto-PG compounds).
Typical examples of the compounds used in the present invention are 15-keto-PGA, 15-keto-PGD, 15-keto-PGE, 15-keto-PGF, 13,14-dihydro-15-keto-PGA, 13,14-dihydro-15-keto-PGD, 13,14-dihydro-15-keto-PGE, and 13,14-dihydro-15-keto-PGF, wherein PG is as defined above as well as their substitution products or derivatives.
Examples of substitution products or derivatives include esters of the carboxy group at the alpha chain, pharmaceutic-ally or physiologically acceptable salts, unsaturated derivatives having a double bond or a triple bond between positions 2 and 3 or positions 5 and 6, respectively, substituted derivatives having substituent(s) on carbon atom(s) at position 3, 5, 6, 16, 17, 19 and/or 20 and compounds having lower alkyl or a hydroxy (lower) alkyl group at position 9 and/or 11 in place of the hydroxy group, of the above PGs.
Examples of substituents present in preferred compounds are as follows: Substituents on the carbon atom at position 3, 17 and/or 19 include lower alkyl, for example, C~ 4 alkyl, especially methyl and ethyl. Substituents on the carbon atom at position 16 include lower alkyl e.g. methyl, ethyl, and the like, hydroxy and halogen atom e.g. chlorine, fluorine, aryloxy e.g. trifluoromethylphenoxy, etc. Substituents on the carbon atom at position 17 include halogen atom e.g. chlorine, fluorine, and the like. Substituents on the carbon atom at position 20 include saturated and unsaturated lower alkyl e.g.
C~ 4 alkyl, lower alkoxy e.g. C, 4 alkoxy and lower alkoxy (lower) alkyl e.g. C, 4 alkoxy-C14alkyl. Substituents on the carbon atom at position 5 include halogen atom e.g. chlorine, fluorine and the like. Substituents on the carbon atom at position 6 include oxo group forming carbonyl. Stereo-3 5 chemistry of PGs having hydroxy, lower alkyl or lower (hydroxy) alkyl substituent on the carbon atom at position 9 and/or 11 may be alpha, beta or mixtures thereof.
-~_ 6 2039420 Said derivatives may have an alkoxy, phenoxy or phenylgroup at the end of the omega chain where the chain is shorter than the primary PGs.
Especially preferred compounds are those having a lower alkyl e.g. methyl, ethyl etc., a halogen atom e.g. chloro, fluoro etc. at position 16, those having a halogen atom e.g.
chloro, fluoro etc. at position 17, those having a lower alkyl e.g. methyl, ethyl etc. at position 19, those having a halogen atom e.g. chlorine, fluorine etc. at position 5, those having an oxo group at position 6, those having a lower alkyl, e.g.
methyl, ethyl, and the like at position 20 and those having phenyl or phenoxy which are optionally substituted with halogen or haloalkyl at position 16 in place of the rest of the alkyl chain.
A group of preferred compounds used in the present invention have the formula y ~ R,- A
Z ~ (I) ~ - B - C 0 - R2 wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, Z is hydrogen or halo, A is -CH2OH, -COCH2OH, -COOH or its functional derivative, B is -CH2-CH2, -CH=CH- or -C--C-, R1is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl, R2is saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo-`: ' (lower)alkyl, aryl or aryloxy.
Among the compounds of the above formula, the compounds represented by the following formula are novel and form also part of the present invention.
M
C~2-D-~-(CH2) 2-COO~a E-CO-C-~b-~c L / \
Ql Q2 wherein L and M are hydrogen atom, hydroxy, lower alkyl, hydroxy(lower)alkyl or oxo, provided that at least one of L and M is not hydrogen atom and that the five membered ring may have one or two double bonds, Q1and Q2are hydrogen atom, halogen atom or lower alkyl, D is -CH2-CH2-, -CH=CH-, -C-C- or -CO-CH2-, E is -CH2-CH2- or -CH=CH-, W is -CH2-CH2-CH2-, CH=CH-CH2or -CH2-CH=CH-, Ra is hydrogen atom, lower alkyl, cyclo(lower)alkyl, monocyclic aryl, monocyclic aryl(lower)alkyl or monocyclic aroyl(lower)alkyl, Rb is single bond or lower alkylene, Rc is lower alkyl which is unsubstituted or substituted with halogen, lower cycloalkyl which is unsubstituted or substituted with lower alkyl, monocyclic aryl which is unsubstituted or substituted with halogen or halo-(lower)alkyl, or monocyclic aryloxy which is unsubstituted or substituted with halogen or halo(lower)alkyl, or a pharmaceutically acceptable salt when R1is hydrogen atom.
Since they have a specific profile where they possess only part of the action (e.g. an action treating cataracts) of PGs while lacking the rest of the action, they are useful as selective PGs-like agent.
~~ 8 2039420 In the above formula, the term "unsaturated" in the definitions for R~and R2is intended to include at least one and optionally more than one double bond and/or triple bond isolatedly, separately or serially present between carbon atoms of the main and/or side chains. According to usual nomenclature, unsaturation between two serial positions is represented by denoting the lower number of said two positions, and unsaturation between two distal positions is represented by denoting both of the positions. Preferred unsaturation is a double bond at position 2 and a double or triple bond at position 5.
It is preferred that the group -CH=CH- in D has cis configuration and the group -CH=CH- in E has trans configuration.
lS The term "lower or medium aliphatic hydrocarbon residue"
refers to a straight or branched chain hydrocarbyl group having l to 14 carbon atoms (for a side chain, l to 3 carbon atoms being preferred) and preferably 2 to 8 carbon atoms for R1and 3 to lO carbon atoms for R2.
The term "halo" denotes fluoro, chloro, bromo and iodo.
The term "lower" throughout the specification is intended to include a group having l to 6 carbon atoms unless otherwise specified.
The term "lower alkyl" as a group or a moiety in hydroxy(lower)alkyl, monocyclic aryl(lower)alkyl, monocyclic aroyl(lower)alkyl or halo(lower)alkyl includes saturated and straight or branched chain hydrocarbon radicals containing l to 6, carbon atoms, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.
The term "lower alkylene" refers to the group obtainable by removing a hydrogen atom from the lower alkyl group as defined above and includes e.g. methylene, ethylene, propylene (trimethylene), tetramethylene, 2-methyltetramethylene, pentamethylene, hexamethylene, and the like.
The term "lower alkoxy" refers to the group lower-alkyl-O- wherein "lower" alkyl is as defined above.
The term "halo(lower)alkyl" refers to lower alkyl group as defined above which is substituted with at least one and preferably 1 to 3 halogen atoms as defined above and includes for example, chloromethyl, bromomethyl, fluoromethyl, trifluoromethyl, 1,2-dichloromethyl, 1,2,2-trichloroethyl, chloropropyl, chlorobutyl, chloropentyl, chlorohexyl, and the like.
The term "hydroxy(lower)alkyl" refers to lower alkyl as defined above which is substituted with at least one hydroxy group, e. g. hydroxymethyl, l-hydroxyethyl, 2-hydroxyethyl and lo 1-methyl-1-hydroxyethyl.
The term "lower alkanoyloxy" refers to a group of the formula: RCO-O- wherein RCO- is an acyl group formed by oxidation of a lower alkyl group as defined above, e.g.
acetyl.
The term "cyclo(lower)alkyl refers to a cyclic group formed by cyclization of a lower alkyl group as defined above.
The term "aryl" includes unsubstituted or substituted aromatic carbocyclic or heterocyclic (preferably monocyclic) groups, e.g. phenyl, tolyl, xylyl and thienyl. Examples of substituents are halo and halo(lower)alkyl wherein halo and lower alkyl being as defined above.
The term "aryloxy" refers to a group of the formula: ArO-wherein Ar is aryl as defined above.
The term "monocyclic aryl" includes phenyl unsubstituted or substituted with lower alkyl substituent, for example phenyl, tolyl, xylyl, cumenyl, and the like.
The term "monocyclic aryloxy" refers to a group consisting of monocyclic aryl as defined above and bivalent oxygen -O- combined together, and includes, for example, phenoxy tolyloxy, xylyloxy, cumenyloxy, and the like.
The term "monocyclic aryl(lower)alkyl" refers to a group consisting of monocyclic aryl and lower alkyl, both as defined above, combined together, and includes, for example, benzyl, phenethyl, tolylmethyl, and the like.
The term "monocyclic aroyl(lower)alkyl" refers to a group consisting of monocyclic aroyl such as benzoyl unsubstituted or substituted with lower alkyl substituent and lower alkyl as defined above combined together, and includes phenacyl (benzoylmethyl), toluoylmethyl, xyloylmethyl, and the like.
The term "functional derivative" of carboxy as A, includes salts (preferably pharmaceutically acceptable salts), esters and amides.
Suitable "pharmaceutically acceptable salts" includes conventional non-toxic salts, and may be a salt with an inorganic base, for example an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), ammonium salt, a salt with an organic base, for example, an amine salt (e.g.
methylamine salt, dimethylamine salt, cyclohexylamine salt, benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris(hydroxymethylamino)ethane salt, monomethyl-monoethanol-amine salt, procaine salt, caffeine salt, and the like), a basic amino acid salt (e.g. arginine salt, lysine salt, and the like), tetraalkyl ammonium salt and the like. These salts can be prepared by the conventional process, for example from the corresponding acid and base or by salt interchange.
Examples of the esters are aliphatic esters, for example, lower alkyl ester e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, l-cyclopropylethyl ester, and the like, lower alkenyl ester e.g. vinyl ester, allyl ester, and the like, lower alkynyl ester e.g. ethynyl ester, propynyl ester, and the like, hydroxy(lower) alkyl ester e.g. hydroxyethyl ester, lower alkoxy(lower)alkyl ester e.g. methoxymethyl ester, l-methoxyethyl ester, and the like, and aromatic esters, for example, optionally substituted aryl ester e.g.
phenyl ester, tosyl ester, t-butylphenyl ester, salicyl ester, 3,4-dimethoxyphenyl ester, benzamidophenyl ester and the like, aryl(lower)alkyl ester, e.g. benzyl ester, trityl ester, benzhydryl ester, and the like. Examples of the amides are mono- or di- lower alkyl amides e.g. methylamide, ethylamide, dimethylamide, and the like, arylamide e. g. anilide, toluidide, and lower alkyl- or aryl-sulfonylamide e.g.
A
., methylsulfonylamide, ethylsulfonylamide, tolylsulfonylamide and the like.
Preferred examples of A include -COOH, -COOCH3, -COOCHzCH3~ -COOCH(CH3) 2 and -CONHSO2CH3.
The configuration of the ring and the ~- and/or omega chain in the above formula (I) may be the same as or different from that in the primary PGs. However, the present invention also includes a mixture of a compound having a primary configuration and that of an unprimary configuration.
Examples of the typical compounds of the present invention are 15-keto-PGs, 13,14-dihydro-15-keto-PGs and their e.g. 6-oxo-derivatives, ~2-derivatives, 3R,S-methyl-derivatives, 5R,S-fluoro-derivatives, 5,5-difluoro-derivatives, 16R,S-methyl-derivatives, 16,16-dimethyl-derivatives, 16R,S-fluoro-derivatives, 16,16-difluoro-derivatives, 17S-methyl-derivatives, 17R,S-fluoro-derivatives, 17,17-difluoro-derivatives, l9-methyl-derivatives, 20-methyl-derivatives, 20-ethyl-derivatives, l9-desmethyl-derivatives, 2-decarboxy-2-carboxyalkyl derivatives and 16-desbutyl-16-phenoxy derivatives.
When 15-keto-PG compounds of the present invention have a saturated bond between positions 13 and 14, these compounds may be in the keto-hemiacetal equilibrium by forming a hemiacetal between hydroxy group at position 11 and ketone at position 15.
The proportion of both tautomeric isomers, when present, varies depending on the structure of the rest of the molecule or kind of any substituent present and, sometimes, one isomer may predominantly be present in comparison with the other.
However, in this invention, it is to be appreciated that the compounds used in the invention include both isomers.
Further, while the compounds used in the invention may be represented by a structure or name based on keto-form regardless of the presence or absence of the isomers, it is to be noted that such structure or name does not intend elimination of the hemiacetal type of compounds.
In the present invention, any of the individual tautomeric isomers, a mixture thereof, or optical isomers, a mixture thereof, a racemic mixture, and other isomers such as steric isomers can be used in the same purpose.
Some of the compounds used in the present invention may be prepared by the method disclosed in Japanese patent publications (une~m;ned) No. A-52753/1989, A-104040/1989, A-151519/1989.
Alternatively, these compounds may be prepared by a process analogous to that described herein or to known processes.
A practical preparation of the 15-keto compounds involves the following steps; referring to the Synthetic Charts I to III, reaction of the aldehyde (2) prepared by the Collins oxidation of commercially available (-)-Corey lactone (1) with dimethyl (2-oxoheptyl)phosphate anion to give a,~-unsaturated ketone (3), reduction of the ~,~-unsaturated ketone (3) to the corresponding saturated ketone (4), protection of the carbonyl group of the ketone (4) with a diol to the corresponding ketal (5), and deprotection of the p-phenylbenzoyl group to give the corresponding alcohol (6) followed by protection of the newly derived hydroxy group with dihydropyrane to give the corresponding tetrahydropyranyl ether (7). According to the above process, a precursor of PGEs wherein the ~ -chain is a 13,14-dihydro-15-keto-alkyl group iS prepared.
Using the above tetrahydropyranyl ether (7), 6-keto-PGE1s (15) of which a group constituted with carbon atoms at positions 5, 6 and 7 is -5CHz-6C(O)-7CH2-, may be prepared in the following steps; reduction of the tetrahydropyranyl ether (7) with, for example, diisobutyl aluminum hydride to give the corresponding lactol (8), reaction of the lactol (8), with the ylide generated from (4-carboxybutyl)triphenyl phosphonium bromide followed by esterification (10), cyclization between the 5,6-double bond and the hydroxyl group at position 9 with NBS or iodine to give the halogenated compound (11), dehydrohalogenation of the compound (11) with, for example, DBU to give the 6-keto compound (13) followed by Jones oxidation and removal of the protecting groups.
Furthermore, PGEzs (19) of which a group constituted with carbon atoms at positions 5, 6 and 7 is -~H2-C6H=C5H- may be prepared in the following steps; as shown in the Synthetic Chart II, reduction of the above tetrahydropyranyl ether (7) to give the lactol (8), reaction of the resultant lactol (8) with the ylid derived from (4-carboxybutyl-)triphenyl phosphonium bromide to give the carboxylic acid (16) followed by esterification to give ester (17), Jones oxidation of the esters (17) to give the compound (18), and removal of the protecting groups.
Using the above tetrahydropyranyl ether (7) as the starting material, the compound having -~H2- g2-5CH2- may be prepared by using the same process as that for preparing PGE2having -CH2CH=CH- and subjecting the resultant compound (18) to catalytic reduction to reduce the double bond between the positions 5 and 6 followed by removal of the protective groups.
Synthesis of 5,6-dehydro-PGE2s having =~H2-=-5C- may be carried out by capturing a copper enolate formed by 1,4-addition of a monoalkylcopper complex or a dialkylcopper complex of the following formulae:
CU~ >~G Cu~/G
O O O O
I I , I I /~
wherein G is alkyl, to 4R-T-butyldimethylsilyloxy-2-cyclopenten-1-one with 6-alkoxycarbonyl-l-iodo-2-hexyne or the derivatives.
The 11-~ type PGEs can be prepared according to the Synthetic Chart III.
PGE derivatives having a methyl group at position 11 in place of hydroxy can be prepared by reacting a dimethyl copper complex with PGA-type compound obtained by subjecting 9-hydroxy-11-tosylate to the Jones oxidation. Alternatively, they can be prepared by protecting the carbonyl of saturated ketone (4) produced by reducing unsaturated ketone (3), eliminating p-phenylbenzoyl and tosylating the produced alcohol, treating with DBU to form a lactol, introducing the alpha-chain by Wittig reaction, oxidizing the alcohol at position 9 to give a PGA-type compound, and reacting the product with dimethyl copper complex in order to introduce a methyl group into position 11 to give an ll-methyl-PGE-type compound, which on reduction with e.g. sodium borohydride, gives an 11-methyl-PGF-type compound. An ll-hydroxymethyl-PGE-type compound, is obtained by a benzophenone-sensitized photoaddition of methanol of PGA-type compound, which is reduced with, e.g. sodium borohydride, to give an 11-hydroxymethyl-PGF-type compound. The 16-mono- or 16,16-di-halo type PGEs can be prepared according to the synthetic chart IV. The synthetic route for the compounds used in the present invention is not limited to that described above one and may vary using different protecting, reducing and/or oxidizating methods.
Furthermore, the novel compounds of the formula II may be prepared by processes shown in the following Synthetic Charts V to XIII, wherein P1, P2, P3, P4, P5, P6 7 protective groups and Q1, Q2~ Rb and Rc are the same as defined above.
Referring to Synthetic Chart V, the compound (41) (for example, a compound wherein Q1and Q2are hydrogen is the compound 8 described in Synthetic Chart I on page 37 of JP-A-52753/1989) is reacted with a ylid produced from (6-carboxyhexyl)triphenylphosphonium bromide to form the compound (42), which is esterified to give the compound (43), which, on removal of the protective groups, can give the compound (44).
Also, referring to Synthetics Chart VI, the above compound (43) is oxidized by Jones oxidation to form the compound (45), ~`
-which can then form the compound (46) by removal of the protective groups. The compounds wherein W is -CH=CH-CH2- or -CH2-CH=CH- can be prepared by reacting the compound ( 41) with a ylid produced from (6-carboxy-2-hexenyl)triphenylphosphonium bromide or (6-carboxy-3-hexenyl)triphenylphosphonium bromide, respectively, and treating the formed compound in a manner similar to that above.
In another example, referring to Synthetic Chart VII, the compound (48), obtained by deprotecting the compound (47) which is commercially available, is oxidized by Swern oxidation to give the aldehyde (49), which is reacted with 2-oxoheptyl phosphonate (for example, 3,3-dihalogenated derivative) to give the compound (50). Catalytic reduction of it gives the compound (51), the ketone moiety of which is reduced by sodium borohydride to form the compound (52). This is further reduced by diisobutylaluminum hydride to give the lactol (53). On reaction with carboxyhexylphosphonium bromide, it gives the compound (54), which is esterified to the compound (55), oxidized to the compound (56) and deprotected to the compound (46). If desired, this can be hydrolyzed to the free acid ( 57). Also, in the Synthetic Chart VIII, the above compound (55) can be catalytically hydrogenated to form the compound (58), which is oxidized by Swern oxidation to give the compound ( 59) and then deprotected to form the desired compound (60).
In the above process, when the reduction in the step from the compound ( 50) to the compound (41) is omitted, a compound wherein Z is -CH=CH- is obtained.
Further, when the compounds of the formula (I) wherein L
is other than OH (for example, lower alkyl) are desired, the lactone moiety in the compound obtained by removing the protective group at position 11 and introducing a protective group in position 15 of the compound (52) is reduced to lactol and then an ~-chain is introduced to the product by Wittig reaction. Then the hydroxy group at position 11 is protected by a lower alkane- or monocyclic aryl-sulfonate group and the product is subjected to oxidation (for example, Jones) to give .~, a 10-en-9-one compound, which is reacted with lower alkyl lithium to form a 11-lower alkyl compound. Compounds of PGD-type can be obtained by oxidizing the 11-deprotected compounds. Compounds of PGA-type can be obtained from the 10-en-9-one compounds. In addition, as shown in Synthetic Chart IX, 6-keto compounds can be obtained by reacting the compound (43) with N-bromosuccinimide or iodine to form the compound (61), followed by treatment with DBU. The 5,6-dehydro (i.e.
acetylenic) compounds can be prepared, according to Synthetic Chart X, by reacting the copper enolate, formed by reacting the compound (63) with a copper complex, with 8-alkoxycarbonyl-1-iodo-2-octyne. Saturated ~-chain introducing agent are prepared as shown in Synthetic Chart XI.
In a further example, according to Synthetic Chart XII, the hydroxy group at position 15 of the compound (52) is protected (for example, by silyl protective group) to form the compound (65) and lactone moiety of which is reduced to lactol giving the compound (66), which is then reacted with an ~-chain introducing agent (for example, a ylid produced from (6-carboxyhexyl)triphenyl phosphonium bromide) to give thecompound (67). Then the carboxy group is protected to form the compound (68) and the hydroxy group at position 9 is protected to form the compound (69). The protective group at position 15 is removed to give the compound (70), which is oxidized to the compound (71). Deprotection at positions 9 and 11 gives the desired compound (72).
Further, as shown in Synthetic Chart XIII, the compound (54) obtained as in Synthetic Chart VII is protected with a protective group removable by catalytic hydrogenation (for example, benzyl) to form the compound (55), which is oxidized at position 9 and deprotected at position 11 to give the compound (46). Catalytic hydrogenation of this compound gives the desired compound (73).
Corresponding other PG compounds can be produced analogously.
,, - 17- o 2039420 "~ ô
0111 11110 ~
~ ^ o ~"~
~t~ttlo ~ ~ ~
- o~ ~ 3 , ~
\o~ 1111 ~
o~""~, ~ Xo~ ~>
dll Illlo C ~
~-o r~
0~ olll11110 ~ o~< ~ ~
~ o o U~
o~
~
o(llOl~llo o V~
~o tll~1t~10 O
~ ~
.~ ~
t" . .
~, - ly C=:
o ~o oi~ o ~
~
~ Itl~-~
h ~ ~<~
o~ o-G_~' e) 0~;",~ ~_ U~
~`
:~,.
J ~
~,~ ~ - /o~
o ] ~ o ~ '~ _ ~ "~( - o ~o ~ ~
-Synthetic Chart rv 2 0 3 9 4 2 0 o o o ,o~ ,o~ ,o~
Q OSiR3 ~ OH Q CHO
THPO THPO THPO
(28) (29) (30) O O
,0~ ,0~
THPO O THPO O
(31) (32) OH
0~0 ' ,0 r ~
THPO ~ THPO
OH OH
(33) (34) HO
~ ~ ^~==-'^`-~ ~ COOH
"~
THPO
OH
(35) HO
, ~~
THPO
OH
(36) o ~ ~ F F COOR
,~
THPO o (37) o ~r ~\ COOR
F F
.:
HO
(38) o ~ ~ COOR
HO o (39) \~ ~ COOH
~ FF
"~
HO o (40) Synthetic Chart V 2 0 3 9 4 2 0 OH
,0~
r Ql Q2 ~<Rb--Rc P~O O O
P2 (41) OH
COOH
Ql Q2 >
~Rb--Rc P10 o O
P2 (42) OH
~\~~` COOP3 - <~ Ql Q2 -~Rb-Rc P,O O O
P2 (43) OH
~~~ COOP3 ~r Ql Q2 ~ Rb--Rc HO
(44) -Synthetic Chart VI
p O Rb-Rc O O
P2 (45) ~ ~COOP3 HO\~>< Rb--Rc o (46) - 25 ~ 2039420 Synthetic Chart V~
O O O
~ Op 4 OH ~ CHO
P10 P10 PlO
(47) (48) (49) O'- O
~)"' QIQ2 > ~ QIQ2 Pl ~ Rb-Rc P O ~ Rb-Rc (50) (51) O OH
,0~ ' ,0~
~ Q~ Q2 > Q QI Q2 ~
Rb-Rc p, OH OH
(52) (53) HO
~ 4 4 COOH
PlO ~ Rb-~c OH
(54) ^`-=="-`-'^`-'" COOP3 ~" QI Q2 P,0 ~ Rb-Rc OH
(55) ~-o P l (~o Rb -Rc (56) (46) ~ ~COOH
> ~ ~ Ql Q2 H~o <Rb-Rc (57) Synthetic Chart Vll (55)~ <~ QIQ2 PIO~><Rb--Rc OH
(58) > ~"' QIQ2 p o~>~Rb--Rc - (59) - ~ ~ ~ Ql Q2 ~><Rb--Rc HO O
(60) .~
~ 28- 2039420 Synthetic Chart lX
Br ~ ~ ~ ,COOP3 (43) ~ <> Ql Q2 P o ~'>~ Rb - Rc P2 (61) OH :~~~/~ COOP3 "' O
\~< Rb--Rc P~O O O
P2 (62) A
t~ -- 29 ~ ~03~420 Synthetic Chart X
Ql Q2 i) Cu ~ Rb - Rc O O O
\ P2 (a) /n(n=1,2) >
PsO ~ =' ~ ~ ~ ' ~ COOP3 (63) (b) > ~ I COOP3 Rb - Rc P 2 (64) Synthetic Chart ~1 Br~ '~ " CN ~ Br-'~~ " COOH
(c) (d) ~~~~ ~ COOH
Br P Ph3 (e) Synthetic Chart Xl[ 2 0 3 9 4 2 0 ,o~
(52) ~ <~ Ql Q2 >
P I O~><Rb--Rc - (65) OH
,0~
<~ Q~ Q2 P I O~XRb-Rc (66) HO
<> ~) Q COOH
p I o~XRb -Rc >
(67) HO
~ --COOP3 ~" Ql Q2 P I o ~ ~Rb-Rc (68) F~`
~----COOP3 P I O~><Rb-Rc (69) p o ~Rb-Rc OH
(70) ~----~COOP3 p, o o~Rb-Rc (71) ~ ~COOP3 HO--I~<Rb-Rc (72) ~' ~ 31a ~
Synthetic Chart ~II 2 0 3 9 4 2 0 (54) ~ (55) ~ (56) > (46)~
~COOH
- - ~ Ql Q2 HO ~Rb-Rc (73) :,~
32 ~0 ~420 Since the compounds used in the present invention have an activity useful for preventing or curing cataracts, these can be used for preparing a medicament for treating cataracts.
Such activities can be measured by the standard methods such as galactose-induced cataract of rats.
The compounds used in the present invention may be used as a medicine for animals and human beings and usually applied systemically or locally by such methods as ophthalmic administration, oral administration, intravenous injection (including instillation), subcutaneous injection, suppository and the like. While the dosage will vary depending on the particular animal or human patient, age, body weight, symptom to be treated, desired therapeutic effect, administration route, term of treatment and the like, satisfactory effects will be obtained with the dosage of 0.01 - 100 ~g/eye administered locally or 0.001 - 500 mg/kg administered systemically in 2 to 4 divided doses a day or as a sustained form.
The ophthalmic composition used according to the invention includes ophthalmic solution, ophthalmic ointment and the like. The ophthalmic solution can be prepared by dissolving an active ingredient in a sterile aqueous solution such as a physiological saline or a buffered solution, or as a combination of a solid and a solution for dissolving said solid to make a ready-to-use preparation. The ophthalmic ointment can be prepared by mixing an active ingredient with an ointment base.
The solid composition for oral administration used according to the invention includes tablets, troches, buccals, capsules, pills, powders, granules and the like. The solid composition contains one or more active substances in admixture with at least an inactive diluent, e.g. lactose, mannitol, glucose, hydrocypropyl cellulose, fine crystalline cellulose, starch, polyvinyl pyrolidone, and magnesium aluminate metasilicate. The composition may contain additives, in addition to the inactive diluent, for example, lubricants e.g., magnesium stearate, a disintegrator e.g.
~' cellulose calcium gluconates, stabilizers e.g. ~ - or r-cyclodextrins, etherated cyclodextrins (e.g. dimethyl-~-, dimethyl-~-, trimethyl-~-, or hydroxypropyl-~-cyclodextrins), branched cyclodextrins (e. g. glucosyl- or maltosyl-cyclodextrins), formyl cyclodextrins, sulfur-containing cyclodextrins, misoprotols or phospholipids. Such cyclodextrins may increase the stability of the compounds by forming an inclusion compounds. The stability may be often increased by forming lyposome with phospholipids. Tablets and pills may be coated with an enteric or gastroenteric film e.g.
white sugar, gelatin, hydroxypropylcellulose, hydroxy-propylmethylcellulose phthalates and the like, if necessary, and furthermore they may be covered with two or more layers. Additionally, the composition may be in the form of capsules made of substance easily absorbed e.g. gelatin.
The composition may be in the form of buccals, when an immediate effect is desired. For this purpose, base e.g.
glycerine, lactose may be used.
Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like and contain a commonly used inactive diluent e.g. purified water or ethyl alcohol. The composition may contain additives e.g. wetting agents, suspending agents, sweeteners, flavors, perfumes and preservatives.
The composition of the present invention may be in the form of sprays which may contain one or more active ingredients and which can be prepared according to well known methods.
An injection of this invention for non-oral administration includes sterile aqueous or nonaqueous solutions, suspensions, and emulsions. Diluents for the aqueous solution or suspension include, for example, distilled water for injection, physiological saline and Ringer's solution. Diluents for the nonaqueous solution and suspension include, for example, propylene glycol, polyethylene glycol, vegetable oils e.g. olive oil, alcohols, e.g. ethanol and A
polysorbates. The composition may contain other additives, e.g. preservatives, wetting agents, emulsifying agents, dispersing agents and the like. These are sterilized by filtration through, e.g. a bacteria-retaining filter, compounding with a sterilizer, gas sterilization or radiation sterilization. These can be prepared by producing a sterilized water or a sterilized solvent for injection before use.
Another formulation according to the present invention is a rectal or vaginal suppository. This can be prepared by mixing at least one active compound according to the invention with a suppository base e.g. cacao butter and optionally containing nonionic surfactant for improving absorption.
A more complete understanding of the present invention can be obtained by reference to the following Preparation Examples, Formulation Examples and Test Examples which are provided herein for purpose of illustration only and are not intended to limit the scope of the invention.
Preparation Example I
Preparation of 16,16-difluoro-13,14-dihydro-15-keto-PGE1methyl ester (39) 1-1) Preparation of (lS,5R,6R,7R)-6-hydroxymethyl-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]octan-3-one (29) To a solution of (-) commercial Corey lactone (THP-form 37.9g) in tetrahydrofuran was added a solution (1.0 M, 300 ml) of tetrabutylammonium fluoride in tetrahydrofuran and the resultant mixture was stirred at room temperature for 3 hours.
The resultant mixture was then concentrated under reduced pressure and the residue subjected to column chromatography to give the titled compound (29).
Yield: 21.70g (82.8%).
1-2) Preparation of (lS,5R,6R,7R)-6-((E)-4,4-difluoro-5-oxo-2-octenyl}-7-tetrahydropyranyloxy-2-oxabicyclo [3.3.0]octan-3-one (31) A solution (2.0 M, 45.5 ml) of oxalyl chloride in methylene chloride was diluted with methylene chloride under ~' -35 2 ~3 ~420 an argon atmosphere at -78C. To this solution was added dropwise dimethylsulfoxide (12.9 ml) and the resultant mixture stirred for 10 minutes. A solution (lS, 5R, 6R, 7R)-6-hydroxymethyl-7-tetrahydropyranyloxy-2-oxabicylot3.3.0]octan-3-one (29) (11.65 g) in methylene chloride was added dropwise and the mixture was stirred for 30 minutes. Then triethylamine (56 ml) was added dropwise and stirring was continued for a further 1 hour. The resultant mixture was worked up with the conventional procedure to give the crude aldehyde product (30).
To a solution of thallium ethoxide (3.26 ml) in methylene chloride was added under an argon atmosphere dimethyl 3,3-difluoro-2-oxoheptylphosphonate (11.9 g) and the resultant mixture was stirred for 1 hour. After cooling the solution to 0C, a solution of the aldehyde (30) obtained above in methylene chloride was added dropwise to said solution and the mixture was stirred at room temperature for 14 hours. The reaction mixture was treated with acetic acid, celite and a saturated aqueous potassium iodide solution and filtered. The filtrate was worked up with the conventional procedure and the crude product was subjected to column chromatography to give the titled compound (31).
Yield: 7.787 g (44.3 %).
1-3) Preparation of (lS,5R,6R,7R)-6-(4,4-difluoro-5-oxo-octyl)-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]octan-3-one (32) To a solution of (lS,5R,6R,7R)-6-~(E)-4,4-difluoro-5-oxo-2-octenyl}-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]octan-3-one (31) (5.57 g) in ethyl acetate was added 5% Pd/C
(catalytic amount) and the resultant mixture was shaken under a hydrogen atmosphere at room temperature for 7 hours. The resultant mixture was filtered and the filtrate was concen-trated under reduced pressure to give the titled compound (32) as a crude product. Yield: 5.48 g (97.8%).
1-4) Preparation of (lS,5R,6R,7R)-6-{4,4-difluoro-5(RS)-hydroxyoctyl~-7-tetrahydropyranyloxy-2-oxabicyclo-[3.3.0]-octan-3-one (33).
~'--To a solution of (lS,5R,6R,7R)-6-(4,4-difluoro-5-oxooctyl)-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]octan-3-one (32) (5.48 g) in methanol was added sodium borohydride (0.800 g) at 0C and the resultant mixture was stirred for lO
minutes. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to column chromatography to give the titled compound (33). Yield: 5.46 g (99.5%).
1-5) Preparation of 16,16-difluoro-13,14-dihydro-11-0-tetra-hydropyranyl-PGF2~ methyl ester (36) A solution of (lS,5R,6R,7R)-6-{4,4-dihydro-5(RS)-hydroxyoctyl}-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]-octan-3-one (33) (2.579 g) in toluene was cooled to -78C under an argon atmosphere. To this solution was added dropwise a solution (1.5 M, 9.6 ml) of diisobutylaluminum hydride in toluene and stirred for 30 minutes. The resultant mixture was worked up with methanol and a saturated aqueous Rochelle salt solution. Then the resultant solution was worked up with the conventional procedure to give the crude lactol product (34).
To a suspension of 4-carboxybutyl triphenyl phosphine bromide (11.72 g) in tetrahydrofuran was added dropwise under an argon atmosphere a solution (1.0 M, 52.84 ml) of potassium tert-butoxide in tetrahydrofuran and the resultant mixture was stirred for 20 minutes. The solution was cooled to 0C and combined with a solution of lactol (34) in tetrahydrofuran.
The resultant mixture was stirred at room temperature for 15 hours and then worked up with the conventional procedure to give the crude carboxylic acid product (35).
To a solution of the carboxylic acid (35) in acetonitrile was added under an argon atmosphere 1,8-diazabicyclo[5.4.0]
undec-7-ene (DBU) (4.0 ml) and methyl iodide (1.7 ml) and the resultant solution was stirred at 60C for 30 hours. The resultant solution was worked up with the conventional procedure and the residue was subjected to column chromatography to give the titled compound (36).
Yield: 2.737 g (84.5%).
~,' .
1-6) Preparation of 16,16-difluoro-13,14-dihydro-15-keto-11-0-tetrahydropyranyl-PGE2methyl ester (37) To a solution of Collins reagent, prepared from chromic anhydride (16.18 g) and pyridine (26.2 ml) in the conventional process, in methylene chloride was added a solution of 16,16-difluoro-13,14-dihydro-ll-O-tetrahydropyranyl-PGF2amethyl ester (36) (2.646 g) in methylene chloride under an argon atmosphere at -20C. The resultant mixture was stirred at the same temperature for 2 hours and at -5C for 9 hours. The solution was treated with ether and sodium hydrogen sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was subjected to column chroma-tography to give the titled compound (37). Yield: 1.890 g (64.4%).
1-7) Preparation of 16,16-difluoro-13,14-dihydro-15-keto PGE2 methyl ester (38).
Into a mixed solvent of acetic acid : water : tetra-hydrofuran (3:1:1) was dissolved 16,16-difluoro-13,14-dihydro-15-keto-ll-0-tetrahydroxypyranyl-PGE2methyl ester (37) (2.809 g) and the resultant solution was stirred at 60C for 5 hours.
The resultant mixture was concentrated under reduced pressure and the residue was subjected to chromatography to give the titled compound (38).
Yield: 1.755 g (75.5%).
1-8) Preparation of 16,16-difluoro-13,14-dihydro-15-keto PGE1methyl ester (39) To a solution of 16,16-difluoro-13,14-dihydro-15-keto-PGE2 methyl ester (38) (1.755 g) in ethyl acetate was added Pd/C
(catalytic amount) and the mixture was shaken under a hydrogen atmosphere at room temperature for 6 hours. The resultant mixture was filtered. The filtrate was concentrated and the residue was subjected to column chromatography to give the titled compound (39). Yield: 1.655 g (93.8%).
1H NMR(CDCl3) ~0.87(3H,t,J=7Hz), 1.15-2.05(23H,m), 2.11-2.30(3H,m), 2.50(lH,dd,J=7.5 and 17Hz), 3.10-3.20 (lH,br), 3.71(3H,s), 4.05-4.20(lH,m) MS(DI-EI) m/z 404(M), 355 (~-H20-CH30), 297(M'-C5H9F2) ~:' .. --Preparation Example 2 Preparation of 16,16-difluoro-13,14-dihydro-15 keto-PGE1 (40) 2-1) Preparation of (15RS)-16,16-difluoro-13,14-dihydro ll-O-tetrahydropyranyl-PGF2abenzyl ester (36) To a solution of 16,16-difluoro-13,14-dihydro-11-O-tetrahydropyranyl-PGF2Q(35) (2.33 g) in dichloromethane (300 ml) were added DBU (2.1 ml) and benzyl bromide (2.2 ml) and the resultant mixture was stirred at room temperature for 1.5 hours. The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the titled compound (36).
Yield: 2.522 g (96.1%).
2-2) Preparation of 16,16,difluoro-13,14-dihydro-15-keto-11-0-tetrahydropyranyl-PGE2benzyl ester (37) Collins reagent was prepared by using chromic anhydride (13.5 g) and pyridine (21.8 ml) in dichloromethane (300 ml), and to this were added Celite (40 g) and (15RS)-16,16-difluoro-13,14-dihydro-11-0-tetrahydropyranyl-PGFz~ benzyl ester (36) (2.550 g). The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the titled compound (37). Yield: 1.991 g (78.6%).
2-3) Preparation of 16,16-difluoro-13,14-dihydro-15-keto-PGE2benzyl ester (38) Into a mixed solvent of acetic acid:THF:water (3:1:1, 50 ml) was dissolved 16,16-difluoro-13,14-dihydro-15-keto-11-O-tetrahydropyranyl-PGE2benzyl ester (37) (1.550 g) and the solution was kept at 50C for 4 hours. The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the titled compound (38). Yield: 1.225g (92.9%).
2-4) Preparation of 16,16-difluoro-13,14-dihydro-15-keto-PGE
(40) To a solution of 16,16-difluoro-13,14-dihydro-15-keto-PGE~
benzyl ester (38) (0.844 g) in ethyl acetate (30 ml) was added 5% Pd/C and the mixture was shaken under a hydrogen ~.
, -- 2~39420 atmosphere. The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the titled compound (43).
Yield: 0.404 g.
1H NMR(CDCl3) ~0.94 (t,3H,J=7.5 Hz), 1.20-2.70 (m,26H), 4.19 (m,lH), 4.80 (br,2H).
MS(DI-EI) m/z 390(M'), 372(M+-H20), 354(M'-2H20).
PreParation Example 3 Preparation of 20-ethyl-2-decarboxy-2-(2-carboxy-ethyl)-13,14-dihydro-15-keto-PGF2a isopropyl ester (44) [IUPAC
nomenclature: isopropyl (Z)-9-(lR)-[(2R,3R,5S)-3,5-dihydroxy-2- (3-oxodecyl)cyclopentyl]-7-nonenoate].
3-1) Preparation of (Z)-9-(lR)-[(2R,3R,5S)-2-(3,3-ethylene-dioxydecyl)-5-hydroxy-3-(tetrahydropyranyloxy)cyclopentyl]-7-nonenoic acid (42) Sodium hydride (60%, 0.422g) was washed with hexane under an argon atmosphere. To this was added dimethyl sulfoxide (DMSO, lOml) and the resultant mixture was kept at 60C for 3 hours. After cooling to room temperature, the resultant mixture was treated with 6-carboxyhexyltriphenylphosphonium bromide (2.49g), stirred at room temperature for 2 hours, then at 45C for 1 hour, and poured into ice-water. The resultant mixture was worked up with the conventional procedure to give the titled compound (42). Yield: 1.68g.
3-2) Preparation of isopropyl (Z)-9-(lR)-[(2R,3R,5S)-2-(3,3-ethylenedioxydecyl)-5-hydroxy-3-(tetrahydropyranyloxy)-cyclopentyl]-7-nonenoate (43) The compound (42) (1.68g) was esterified in the conventional procedure with 1,8-diazabicyclo[5.4.0]-7-undecene (DBU, 0.78ml) and isopropyl iodide (0.35ml) in acetonitrile (15ml). The residue was subjected to silica gel column chromatography to give the titled compound (43). Yield:
0.908g (88%) 3-3) Preparation of isopropyl (Z)-9-(lR)-[(2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-7-nonenoate (44) The compound (43) (0.305g) was dissolved in a mixed solvent (6ml) consisting of acetic acid, THF and water (2:1:1) ~,-203 942~
and kept at 50C for 14 hours. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chroma-tography to give the titled compound (44). Yield: 0.213g 5 (90%).
Compound (44) [Q1=Q2=H, Rb-Rc=hexyl, P3=isopropyl]
1H NMR(CDC13)~: 0.85 (t,3H,J=6.5Hz), 1.20 (d,6H,J=6Hz), 1.23-2.65 (m,34H), 3.86 (m,lH), 4.16 (m.lH), 4.99 (Hept,lH,J=6Hz), 5.39 (m,2H).
Preparation Example 4 Preparation of 20-ethyl-2-decarboxy-2-(2-carboxy-ethyl-13,14-dihydro-15-keto-PGE2isopropyl ester (46) [IUPAC
nomenclature: isopropyl (Z)-9-(lR)-[(2R,3R)-3-hydroxy-5-oxo-2-(3-oxodecyl)cyclopentyl]-7-nonenoate]
4-1) Preparation of (Z)-9-(lR)-[(2R,3R)-2-(3,3-ethylene-dioxydecyl)-5-oxo-3-(tetrahydropyranyloxy)cyclopentyl]-7-nonenoate (45) Oxalyl chloride (2M, 0.45ml) and DMSO (0.13ml) were added to dichloromethane (5ml) cooled previously to -70C and the resultant mixture was stirred for 15 hours. A solution of isopropyl (Z)-9-(lR)-[(2R,3R,5S)-2-(3,3-ethylenedioxydecyl)-S-hydroxy-(3-tetrahydropyranyloxy)-cyclopentyl]-7-nonenoate (43) (0.35g) in dichloromethane (7ml) was added dropwise to the above solution. After stirring at -55C for 15 minutes, the resultant mixture was treated with triethylamine (0.25ml) and warmed up to 10C over 6 hours. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (45). Yield:
0.311g (89%).
4-2) Preparation of isopropyl (Z)-9-(lR)-[(2R,3R)-3-hydroxy-5-oxo-2-(3-oxodecyl)cyclopentyl]-7-nonenoate (46) The compound (45) (0.311g) was dissolved in a mixed solvent (5ml) consisting of acetic acid, THF and water (2:1:1) and kept at 50C for 3 hours. The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the ,~
41 ' 2039420 titled compound (46). Yield: 0.156g (66%). Compound (46) [Q1=Q2=H, Rb-Rc=hexyl, P3=isopropyl]
H NMR(CDC13)~: 0.86 (t,3H,J=6.5Hz), 1.20 (d,6H,J=6Hz), 1.23-2.75 (m,33H), 4.20 (m,lH), 4.99 (Hept,lH,J=6Hz), 5.15-5.50 (m,2H).
Preparation Example 5 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13, 14-dihydro-16,16-difluoro-15-keto-PGE2(47) tIUPAC
nomenclature: (Z)-9-(lR)-[(2R,3R)-2-(4,4-difluoro-3-oxo-octyl)-3-hydroxy-5-oxopentyl]-7-nonenoic acid]
Preparation of starting compound: (6-carboxy-hexyl) triphenylphosphonium bromide (e).
A mixture of 7-bromoheptanonitrile (c) (lO.Og) and 40%
hydrobromic acid (80ml) was heated under reflux for 6 hours.
The mixture was diluted with water, extracted with ether and then worked up with the conventional procedure to give a crude product. The residue was subjected to silica gel column chromatography to give 7-bromoheptanoic acid (d). Yield:
7.60g (69%) Treatment of 7-bromoheptanoic acid (d) (7.60g) with triphenylphosphine (lO.Og) gave (6-carboxyhexyl)-triphenylphosphonium bromide (e). Yield: 16.0g (93%).
Preparation of the desired compound 5-1) Preparation of (lS,SR,6R,7R)-6-(4,4-difluoro-3-oxo-octenyl)-7-(tetrahydropyranyloxy)-2-oxabicyclo[3.3.0]-octan-3-one (50) The Swern oxidation of (lS,5R,6R,7R)-6-hydroxy-methyl-7-(tetrahydropyranyloxy)-2-oxabicyclo[3.3.0]octan-3-one (48) (27.8g), which was obtained from commercial (lS,5R,6R,7R)-6-(5-butyldimethylsilyloxymethyl)-7-(tetrahydropyranyloxy)-2-oxabicyclo[3.3.0]octan-3-one (47), using oxalyl chloride (2.0M, 109.3ml), DMS0 (31.0ml) and trimethylamine (150ml) in dichloromethane (800ml) gave the compound (49) (P1=tetrahydropyranyl).
The above compound (49) was reacted with dimethyl 3,3-difluoro-2-oxoheptylphosphonate (30.0g) in dichloromethane in the presence of thallium methoxide (8.23ml). The resultant ,~
-mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (50). Yield: 24.4g (58%).
5 5-2) Preparation of (lS,5R,6R,7R)-6-(4,4-difluoro-3-oxo-octyl)-7-tetrahydropyranyloxy-2-oxabicyclo[3.3.0]octan-3-one (51) The compound (50) (12.7g) was catalytically hydrogenated over 5% palladium on carbon (catalytic amount) in ethyl acetate (300ml) under a hydrogen atmosphere to give the titled compound (51). Yield: 12.5g (99%).
5-3) Preparation of (lS,5R,6R,7R)-6-[4,4-difluoro-3(R,S)-hydroxyoctyl]-7-tetrahydroxypyranyloxy-2-oxabicyclo-[3.3.0]octan-3-one (52) The compound (51) (12.6g) was reduced with sodium borohydride (1.25g) in methanol (400ml) at 0 C to give the titled compound (52). Yield: 12.lg (95.5%).
5-4) Preparation of (lS,5R,6R,7R)-6-[4,4-difluoro-3(R,S)-hydroxyoctyl]-7-tetrahydroxypyranyloxy-2-oxabicyclo-[3.3.0]octan-3(R,S)-ol (53) The compound (52) (12.lg) was reduced with diisobutylaluminum hydride (1.5M, 65.lml) in toluene (500ml) at -78 C and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (53).
Yield: ll.lg (91%).
5-5) Preparation of phenacyl (Z)-9-(lR)-[(2R,3R,5S)-2-~4,4-difluoro-(3RS)-hydroxyoctyl)-5-hydroxy-3-(tetrahydro-pyranyloxy)cyclopentyl]-7-nonenoate (55) Sodium hydride (60%, 1.63g) was washed with pentane. To this was added DMS0 (40ml) and the resultant mixture was kept at 65-70C for 1.5 hours. After cooling to the room temperature, carboxyhexylphosphonium bromide (e) (9.61g) was added to the mixture to form a ylid. A solution of the compound (53) in DMS0 (15ml) was added dropwise to the ylid in solution and the mixture was kept overnight at room temperature. The resultant mixture was worked up with conventional procedure to give the compound (54).
~.
-Yield: 3.18g (crude).
The compound (54) (0.795g), phenacyl bromide (l.Olg) and diisopropylethylamine (0.89ml) were dissolved in acetonitrile (lOml) and the solution was kept at room temperature for 20 minutes and then at 45C for 30 minutes. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silicagel column chromatography to give the titled compound (55).
Yield: 0.604g.
5-6) Preparation of phenacyl (Z)-9-(lR)-[(2R,3R)-2-{4,4-difluoro-3-oxooctyl}-5-oxo-3-(tetrahydropyranyloxy)-cyclopentyl]-7-nonenoate (56) DMSO (0.92ml) was added dropwise to a solution of oxalyl chloride (0.52ml) in dichloromethane (30ml) previously cooled to -78C. The compound (55) (0.609g), dissolved in dichloromethane (15ml), was added to the above solution and the resultant mixture was stirred at -30C to -20C for 1.5 hours. The resultant mixture was treated with triethylamine (1.88ml) and stirred for 30 minutes. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silicagel column chromatography to give the titled compound (56). Yield: 0.514g (85%).
5-7) Preparation of phenacyl (Z)-9-(lR)-[(2R,3R)-2-{4,4-difluoro-3-oxooctyl}-3-hydroxy-5-oxocyclopentyl]-7-nonenoate (46) The compound (56) (0.514g) was dissolved in a mixed solvent (30ml) consisting of acetic acid, THF and water (4:2:1) and the solution was kept overnight at room temperature. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (46). Yield: 0.272g (61%).
Compound (46) [Q1=Q2=F, Rb-Rc=butyl, P3=phenacyl]
1H NMR(CDCl3)~: 0.92 (t,3H,J=7.5Hz), 1.2-2.9 (m,27H), 4.18 (m,lH), 5.4 (m,2H), 7.4-8.0 (m,5H) 5-8) Preparation of (Z)-9-(lR)-[(2R,3R)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]-7-nonenoic acid 57) -A solution of the compound (46) (0.272g) in acetic acid (lOml) was treated with zinc (3.5g) added in portions at room temperature for 2.5 hours. The resultant mixture was worked up with the conventional procedure and the residue was subjected to silica gel column chromatography to give the titled compound (57). Yield: 0.177g (81%). Compound (57) [Q1=Q2=F, Rb-Rc=butyl]
H NMR(CDCl3)~: 0.93(t,3H,J=6.5Hz), 1.15-2.95 (m,28H), 4.19 (m,lH), 5.36 (m,lH) PreParation Example 6 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-16,16-difluoro-15-keto-PGE1isopropyl ester [IUPAC
nomenclature: isopropyl 9-(lR)-[(2R,3R)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]nonenoate 6-1) Preparation of isopropyl (Z)-9-(lR)-[(2R,3R,5S)-2-{4,4-difluoro-(3RS)-hydroxyoctyl}-5-hydroxy-3-(tetrahydropyranyloxy)cyclopentyl]-7-nonenoate (55) The compound (54) (0.802g) obtained in Preparation Example 5, DBU (0.76ml) and isopropyl iodide (0.51ml) were dissolved in acetonitrile (15ml) and kept at 50C for 1 hour. Compound (54) (0.492g) was treated in the same way.
The resultant mixture was worked up with the conventional procedure to give the titled compound (55).
Yield (combined): 0.315g.
6-2) Preparation of isopropyl 9-(lR)-[(2R,3R)-2-{4,4-difluoro-3RS)-hydroxyoctyl}-5-hydroxy-3-(tetrahydropyranyloxy)-cyclopentyl]-7-nonenoate (58) The compound (55) (0.315g) was catalytically hydrogenated over palladium on carbon (5%, 0.08g) in ethanol (20ml) under hydrogen atmosphere to give the titled compound (58).
Yield: 0.301g (95%) 6-3) Preparation of isopropyl 9-(lR)-[(2R,3R)-2-{4,4-difluoro-3-oxooctyl}-5-oxo-3-(tetrahydropyranyloxy)-cyclopentyl]-nonenoate (59) The compound (58) (0.301g) was subjected to Swern oxidation using oxalyl chloride (0.34ml), DMSO (0.61ml) and triethylamine (1.22ml) in dichloromethane to give the entitled -compound (59). Yield: 0.288g (96%).
6-4) Preparation of isopropyl 9(lR)-[(2R,3R)-2-{4,4-difluoro-3-oxooctyl}-3-hydroxy-5-oxocyclopentyl]-nonanoate (60) The compound (59) (0.288g) was dissolved in a mixed solvent (30ml) consisting of acetic acid, water and THF
(4:2:1) and the solution was kept at 45C for 3.5 hours.
The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (60). Yield: 0.184g (76%).
Compound (60) [Q1=Q2=F, Rb-Rc=butyl, P3=isopropyl]
H NMR (CDCl3)~: 0:94 (t,3H,J=6.5Hz), 1.24 (d,6H,J=6Hz), 1.27-2.95 (m,31H), 4.19 (m,lH), 5.02 (Hept,lH,J=6Hz) The compounds of the formula I wherein D is -CO-CH2- and those wherein D is -C--C- can be prepared as follows:
Preparation Example 7 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13, 14-dihydro-6,15-diketo-PGF1Qisopropyl ester The compound (43) obtained in Preparation Example 3 is dissolved in a mixture of anhydrous tetrahydrofuran and anhydrous methylenechloride. A small excess amount of N-bromosuccinimide is added to the solution at 0C and the resultant mixture is stirred for 5 minutes. The resultant mixture is worked up with the conventional procedure and the crude product is subjected to column chromatography to give the compound (61) (Q1=Q2=H, Rb-Rc=butyl, P1=tetrahydroxy-pyranyl, P2=ethylene, P3=isopropyl). This is dissolved in anhydrous toluene. The solution is treated with DBU and stirred overnight at 40 C. After cooling with ice, the solution is acidified with N-HCl, stirred for 10 minutes and extracted with ethyl acetate. The resultant mixture is worked up with the conventional procedure and the residue is subjected to column chromatography to give the compound (62) (symbols having the same meaning as above). Removal of the protective groups in a manner similar to that in the step 3-3) in Preparation Example 3 gives the titled compound.
~,~
-Preparation Example 8 Preparation of 2-decarboxy-2-(2-carboxyethyl)-5,6-dehydro-13,14-dihydro-15-keto-PGE2methyl ester Tert-butyl lithium is added dropwise to a solution of 8-5 methoxy-3,3-ethylenedioxy-1-iodooctane (prepared according to JP-A-52753/1989) in ether at -78C over 30 minutes and the resultant mixture is stirred for 3 hours. Then a solution, cooled to -78~C, of cuprous iodide and tributylphosphine in ether is added to the above mixture in one portion and the resultant mixture is stirred for 20 minutes to form the complex (a). A solution of 4R-tert-butyldimethylsilyloxy-2-cyclopenten-1-one (63) in tetrahydrofuran is added dropwise to the mixture over 95 minutes. The resultant mixture is stirred for 15 minutes and transferred to a cooling bath at -30C. A
solution of $-methoxycarbonyl-1-iodooctyne (b) in HMPA is added to the cooled mixture, which is then stirred for 4.5 hours. Stirring is continued at the room temperature for 12 hours and then the mixture is poured into an aqueous ammonium chloride solution. The organic layer is separated and worked up with the conventional procedure to give a crude product.
The crude product is subjected to column chromatography to give the compound (64) [Q1=Q2=H, Rb-Rc=butyl, P3=methyl, P5=
tert-butyldimethylsilyl]. Deprotection of this in the conventional manner gives the titled compound.
Preparation Example 9 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-16,16-difluoro-15-keto-PGF2amethyl ester (72) [IUPAC
nomenclature: methyl (Z)-9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl)-3,5-dihydroxycyclopentyl]-7-nonenoate 9-1) Preparation of (lS,5R,6R,7R)-6-[3(R,S)-t-butyldimethyl-silyloxy-4,4-difluorooctyl]-7-(tetrahydropyranyloxy)-2-oxabicyclo[3.3.0]octan-3(R,S)-ol (66) The compound (52) [Q1=Qz=F, P1=tetrahydropyranyl, Rb-Rc=butyl] (1.26g) was treated with imidazole (2.63g) and tert-butyldimethylsilyl chloride (2.91g) in DMF (15ml) to give the silyl ether (65). Yield: 1.43g (88%).
The silyl ether (65) (1.43g) was reduced with diisobutyl-.~
203 ~420 aluminum hydride in the conventional procedure to give the titled compound (66). Yield: 1.47g (100%).
9-2) Preparation of methyl (Z)-9-(lR)-[(2R,3R,5S)-2-{3(R,S)-tert-butyldimethylsilyloxy-4,4-difluorooctyl~-5-hydroxy-3-(tetrahydropyranyloxy)cyclopentyl]-7-nonenoate (68) A ylid was prepared from sodium hydride (60%, 0.934g), DMSO (25ml) and (6-carboxyhexyl)triphenylphosphonium bromide (5.50g) in the conventional procedure. The ylid was added to a solution of the compound (66) in ether (8ml) and the resultant mixture was stirred at room temperature for 2 hours.
The resultant mixture was worked with the conventional procedure to give the carboxylic acid (67), which was treated with diazomethane. The product was then subjected to silica gel column chromatography to give the titled compound (68).
Yield: 0.43g (48%).
9-3) Preparation of methyl (Z)-9-(lR)-t(2R,3R,5S)-2-{3(R,S)-tert-butyldimethylsilyloxy-4,4-difluorooctyl}-3,5-(ditetrahydropyranyloxy)cyclopentyl]-7-nonenoate (69) The compound (68) (0.438g) was converted to ditetrahydropyranyl ether using an excess amount of dihydropyran and a catalytic amount of p-toluenesulfonic acid in dichloromethane (25ml). The resultant mixture was subjected to silica gel column chromatography to give the compound (69). Yield: 0.494g (99%).
9-4) Preparation of methyl (Z)-9-(lR)-[(2R,3R,5S)-2-(tert-butyldimethylsilyloxy-3-oxooctyl)-3,5-(ditetrahydro-pyranyloxy)cyclopentyl]-7-nonenoate (71) The compound (69) (0.494g) was dissolved in THF (lOml), tetrabutylammonium trifluoride (l.OM, 5.6ml) added to the solution, and the resultant mixture was kept overnight. The resultant mixture was then worked up with the conventional procedure to give the deprotected compound (70).
Yield: 0.284g (68%).
The compound (70) (0.284g) was subjected to Swern oxidation using oxalyl chloride (0.165ml) and DMSO (0.3ml) in dichloromethane (lOml). The product was subjected to silica gel column chromatography to give the compound (71).
,~.
.
Yield: 0.251g (89%).
9-5) Preparation of methyl (Z)-9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl)-3,5-dihydroxycyclopentyl]-7-nonenoate (72) The compound (71) was dissolved in a mixed solvent (3Oml) consisting of acetic acid, water and THF (4:2:1) and the solution was kept at 45 to 50C for 3 hours. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (72).
Yield: 0.137 (76%).
Compound (72) [Q1=Q2=F, Rb-Rc=butyl, P3=methyl]
H NMR(CDC13)S: O.g2 (t,3H,J=7.5Hz), 1.2-2.9 (m,38H), 3.67 (s,3H), 3.70 (q,lH,J=7.5Hz), 4.25 (m,lH), 5.43 (m,2H) Preparation Example 10 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-16,16-difluoro-15-keto-PGEl(73) [IUPAC nomenclature:
(Z)-9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]nonanoic acid]
10-1) Preparation of benzyl (Z)-9-(lR)-[(2R,3R,5S)-3-{4,4-difluoro-3(R,S-hydroxyoctyl}-5-hydroxy-3-(tetrahydro-pyranyloxy)cyclopentyl]-7-nonenoate (55) The compound (54) [Q1=Q2=F, P1=tetrahydropyranyl, Rb-Rc=butyl] (1.09g) was dissolved in acetonitrile (20ml), and DBU (2.6 ml) and benzyl bromide (2.2ml) were added to the solution. The resultant mixture was kept at 45C for 1 hour and then overnight at 60C. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (65). Yield: 0.213g.
10-2) Preparation of benzyl (Z)-9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl-3-tetrahydropyranyloxy)-5-oxocyclopentyl]-7-nonenoate (56) The compound (55) (0.213g) was subjected to Swern oxidation using oxalyl chloride (0.23ml), DMSO (0.41ml) and triethylamine (0.8lml) in dichloromethane (15ml). The product was subjected to silica gel column chromatography to give the .~ , .
titled compound (56). Yield: 0.181g (86%).
10-3) Preparation of benzyl (Z)-9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]-7-nonenoate (46) The compound (56) (0.181g) was dissolved in a mixed solvent (25ml) consisting of acetic acid, water and THF
(4:2:1) and the solution was kept at 45C for 3.5 hours. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (46). Yield: 0.40g (91%).
Compound (46) [Q1=Q2=F, Rb-Rc=butyl, P3=benzyl]
H NMR(CDC13)~: 0.93 (t,3H,J=7.5Hz), 1.2-2.8 (m,27H), 4.20 (m,lH), 5.12 (s,2H), 5.2-5.5 (m,2H), 7.35 (m,5H) 10-4) Preparation of 9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl-3-hydroxy-5-oxocyclopentyl]nonanoic acid (73) The compound (46) was dissolved in ethyl acetate (15ml). Palladium on carbon (50mg) was added to the solution and shaken under the hydrogen atmosphere. After removing the catalyst by filtration, the filtrate was concentrated and the produced crude product was subjected to Lobar column (ODS) chromatography to give the titled compound (73).
Yield: 0.077g (65%).
Compound (73) [Q1=Q2=F, Rb-Rc=butyl]
1H NMR(CDC13) ~: 0.95 (t,3H,J=7.5Hz), 1.2-2.8 (m,32H), 4.20(m,lH) Preparation Example 11 Preparation of 20-ethyl-2-decarboxy-2-(2-carboxy-ethyl) -13,14-dihydro-16,16-difluoro-15-keto-PGE1isopropyl ester (60) [IUPAC nomenclature: isopropyl (Z)-9-(lR)-[(2R,3R)-2-(4,4-difluoro-3-oxodecyl)-3-hydroxy-5-oxocyclopentyl]-7-nonenoate]
The procedure of Preparation Example 6 was repeated except that dimethyl (3,3-difluoro-2-oxononyl)-phosphonate was used to give the titled compound (60). Compound (60) [Q1=Q2=F, Rb-Rc=hexyl, P3=isopropyl]
1H NMR(CDCl3)~: 0.90 (t,3H,J=7.5Hz), 1.32 (d,6H,J=6Hz), 1.25-2.70 (m,34H), 3.15 (s,lH), 4.20 (m,lH), 5.00 (Hept,lH,J=7.5Hz) ~.~
20J~420 .
Preparation Example 12 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-PGE2isopropyl ester (46) [IUPAC nomenclature:
isopropyl (Z)-9-(lR)-[(2R,3R)-2-(3-oxopentyl)-3-hydroxy-5-oxocyclopentyl]-7-nonenoate]
The procedure of Preparation Example 4 was repeated except that dimethyl 2-oxoheptylphosphonate was used to give the titled compound (46).
Compound (46) [Q1=Q2=H, Rb-Rc=butyl, P3=isopropyl]
1H NMR(CDCl3)~: 0.89 (t,3H,J=6.6Hz), 1.18 (d,6H,J=6.2Hz), 1.15-3.0 (m,29H), 4.04 (m,lH), 4.99 (hept,IH, J=6.2Hz), 5.37 (m,2H) Formulation Example 1 (Powders for injection) (Parts by weight) 13,14-dihydro-15-keto-16,16-difluoro-PGE2 mannitol 5 distilled water 0.4 The above ingredients were mixed, stirred, sterilized, 20 filtered and lyophilized to give powders for injection.
Formulation Example 2 (Injectable solution) (Parts by weight) 13,14-dihydro-15-keto-16,16-difluoro-PGE1 0.2 nonion surfactant 2 distilled water 98 The above ingredients were mixed and sterilized to give an injectable solution.
Formulation Example 3 (Enteric capsules) 13,14-dihydro-15-keto-16,16-difluoro-20-methyl-PGE2 (50mg) dissolved in methanol (lOml) was mixed with mannitol (18.5g).
The mixture was screened (with a sieve, the pore size of which being 30 mm in diameter), dried at 30C for 90 minutes and screened again. The powders thus obtained were mixed with fine-grain silica gel (Aerosil*, 200g) and filled in No.3 hard * Trade-Mark gelatin capsules (100) to give enteric capsules which contain 0.5mg of 13,14-dihydro-15-keto-16,16-difluoro-20-methyl-PGE2 per capsule.
Formulation Example 4 (Powders for oral administration) (Parts by weight) 13,14-dihydro-6,15-diketo-16,16-difluoro-PGE1methyl ester 5 light anhydrous silicic acid 5 Abicel* 20 lactose 70 The above ingredients were mixed to give powders for oral administration.
Formulation ExamPle 5 (Soft gelatine capsules) (Parts by weight) 13,14-dihydro-6,15-diketo-l9-methyl-PGE
methyl ester light anhydrous silicic acid 899 Panasate* 20 The above ingredients were mixed and filled in soft gelatine capsules.
Formulation Example 6 (Enteric capsules) 16-desbutyl-13,14-dihydro-15-keto-16-m-trifluoromethyl-phenoxy-PGFzQmethyl ester (50mg) dissolved in methanol (lOml) was mixed with mannitol (18.5g). The mixture was screened (with a sieve, the pore size of which being 30 mm in diameter), dried at 30C for 90 minutes and screened again.
The powders thus obtained were mixed with fine-grain silica gel (Aerosil , 200g) and filled in No.3 hard gelatin capsules (100) to give enteric capsules which contain 0.5mg of 13,14-dihydro-15-keto-16-desbutyl-16-m-trifluoromethylphenoxy-PGF
methyl ester per capsule.
*Trade-Mark p~.,:, Formulation Example 7 (powders for injection) (Parts by weight) 13,14-dihydro-15-keto-16,16-difluoro-PGE1 1 mannitol 5 distilled water 0.4 The above ingredients were mixed, stirred, sterilized, filtered and lyophilized to give powders for injection.
Formulation Example 8 (Injectable solution) (Parts by weight) 13,14-dihydro-6,15-diketo-5R,S-difluoro-PGE1 0.2 nonion surfactant 2 distilled water 98 The above ingredients were mixed and sterilized to give an injectable solution.
Formulation Example 9 (Powders for oral administration) (Parts by weight) 13,14-dihydro-15-keto-16,16-difluoro-l9-desmethyl-PGE2 methyl ester 5 light anhydrous silicic acid 5 - Abicel* 20 lactose 70 The above ingredients were mixed to give powders for oral administration.
Formulation Example 10 (Soft gelatine capsules) (Parts by weight) 13,14-dihydro-15-keto-16-desbutyl-16-m-trifluoromethylphenoxy-PGE2methyl ester light anhydrous silicic acid 899 Panasate* 20 The above ingredients were mixed and filled in soft gelatine capsules.
* Trade-Mark A~
~ 53 2039420 In the above formulation examples, the active ingredient can be replaced by any other compound within the compounds used in the invention.
Formulation Example 11 (Ophthalmic solution) 13,14-dihydro-15-keto-20-ethyl-PGF2~ 10 mg Physiological Saline 10 ml The above components were placed in separate vials. The vials were combined for preparing a solution on actual use.
Test Example 1 Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 3 groups, each group consisting of 5 or 6 animals (i.e. 10 or 12 eyes). The group 1 was assigned to the normal control group and fed with normal diet. The groups 2 and 3 were fed with 50% galactose diet.
The group 2 subcutaneously received 2 times 5 ml/kg doses (morning and evening) of pure physiological saline, while the group 3 received similarly 2 times doses of 10~g/kg test compound dissolved in 5mg/kg physiological saline. As the test compound, 13,14-dihydro-15-keto-16,16-difluoro-PGE2was used.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque as compared with nuclei of the group 1 animals (control) was taken as the day of onset of cataract. The results are shown in Table 1, in which the numerical values indicate cataract/total eyes.
Table 1 Group (n) Day 1 (6)0/12 - 0/12 0/12 0/12 0/12 0/12 2 (5)0/10 - 0/10 1/10 2/10 5/10 7/10 3 (6)0/12 - 0/12 0/12 0/12 1/12 1/12 It can be seen from the above results that the test compound has an activity inhibiting experimental cataract.
Test Example 2 Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 5 groups, each group consisting of 6 animals (i.e. 12 eyes). Each group was fed with 30% galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
Group Substance Dose/Administration Mode 1 Physiological Saline 5tl/eye ophthalmic 2 Test Compound 1 O.ltg/eye ophthalmic 3 Test Compound 1 lOtg/kg subcutaneous 4 Test Compound 2 6tg/eye ophthalmic 5 Test Compound 3 lOOtg/kg subcutaneous Test Compounds:
1: 13,14-dihydro-15-keto-16,16-difluoro-PGE2methyl ester 2: 13,14-dihydro-15-keto-20-ethyl-PGF2aisopropyl ester 3: 13,14-dihydro-15-keto-20-ethyl-PGF2a The ophthalmic administration was effected with a solution of the test compound dissolved in a physiological saline (5tl/eye), administered 3 times a day. The subcutaneous administration was effected with a solution of the test compound in a physiological saline (5ml/kg), administered twice a day.
The results are shown in Table 2, in which the numerical values indicate cataract/total eyes.
Table 2 Group Day 2039 ~ 20 It can be seen from the above results that the test compounds have an activity inhibiting experimental cataract.
Test ExamPle 3 Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 3 groups, each group consisting of 6 animals (i.e. 12 eyes). Each group was fed with 30% galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
Group Substance Dose/Administration Mode 1 Physiological Saline 5tl/eye ophthalmic 2 Test Compound 4 O.ltg/eye ophthalmic 3 Test Compound 4 lOtg/kg subcutaneous Test Compound:
4: 13,14-dihydro-15-keto-16,16-difluoro-PGE2isopropyl ester The ophthalmic administration was effected with a solution of the test compound dissolved in a physiological saline (5tl/eye), administered 3 times a day. The subcutaneous administration was effected with a solution of the test compound in a physiological saline (5ml/kg), administered twice a day.
The results are shown in Table 3, in which the numerical values indicate rate (in %) of onset of cataract (cataract x 100/total eyes).
Table 3 Group Day It can be seen from the above results that the test compounds have an activity inhibiting experimental cataract.
^~--~ 56 2039¢20 Test Example 4 Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 3 groups, each group consisting of 6 animals (i.e. 12 eyes). Each group was fed with 30% galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
Group Substance Dose/Administration Mode 1 Physiological Saline 5ml/kg subcutaneous 2 Test Compound 5 O.ltg/eye ophthalmic 3 Test Compound 5 lOtg/kg subcutaneous Test Compounds:
5: 13,14-dihydro-15-keto-16,16-difluoro-PGE1methyl ester The ophthalmic administration was effected with a solution of the test compound dissolved in a physiological saline (5tl/eye), administered 3 times a day. The subcutaneous administration was effected with a solution of the test compound in a physiological saline (5ml/kg), administered 4 times a day.
The results are shown in Table 4, in which the numerical values indicate rate (in %) of onset of cataract (cataract x 100/total eyes).
Table 4 Group Day It can be seen from the above results that the test compounds have an activity inhibiting experimental cataract.
A~.
~..
Test ExamPle 5 (ComParative) Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 7 groups. Each group was fed with 40~ galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
Group Substance Animal (eye) Dose/Administration 1 Physiological Saline 10(20) 5ml/kg 2 Test Compound 6 5(10)lOOtg/kg 3 Test Compound 7 5(10)lOOtg/kg 4 Test Compound 8 5(10)lOOtg/kg 5 Test Compound 9 5(10)lOOtg/kg 6 Test Compound 10 5(10)lOtg/kg 7 Test Compound 11 5(10)ltg/kg Test Compounds:
6: PGE1 7: PGDz 8: PGF2a 9: PGA2 10: 16,16-dimethyl-PGE2 11: 6-oxo-17S,20-dimethyl-PGE1 The administration was effected with a solution of the test compound in a physiological saline (5ml/kg), substaneously administered twice a day.
The results are shown in Table 5, in which the numerical values indicate rate (in %) of onset of cataract (cataract x 100/total eyes).
q~ , 203~420 Table 5 Group Day 7 o - O 30 6070 70 It can be seen from the above results that the primary type PGs having a hydroxy group at position 15 have no distinct inhibition and in some cases have, rather, promotion to cataract.
Test Example 6 Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 4 groups, each group consisting of 9 animals (i.e. 18 eyes). Each group was fed with 30% galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
Group Substance Dose/Administration 1 Physiological Saline 5tl/eye 2 Test Compound 12 O.ltl/eye 3 Test Compound 13 O.ltg/eye 4 Test Compound 14 l.Otg/eye Test Compounds:
Yield: 0.301g (95%) 6-3) Preparation of isopropyl 9-(lR)-[(2R,3R)-2-{4,4-difluoro-3-oxooctyl}-5-oxo-3-(tetrahydropyranyloxy)-cyclopentyl]-nonenoate (59) The compound (58) (0.301g) was subjected to Swern oxidation using oxalyl chloride (0.34ml), DMSO (0.61ml) and triethylamine (1.22ml) in dichloromethane to give the entitled -compound (59). Yield: 0.288g (96%).
6-4) Preparation of isopropyl 9(lR)-[(2R,3R)-2-{4,4-difluoro-3-oxooctyl}-3-hydroxy-5-oxocyclopentyl]-nonanoate (60) The compound (59) (0.288g) was dissolved in a mixed solvent (30ml) consisting of acetic acid, water and THF
(4:2:1) and the solution was kept at 45C for 3.5 hours.
The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (60). Yield: 0.184g (76%).
Compound (60) [Q1=Q2=F, Rb-Rc=butyl, P3=isopropyl]
H NMR (CDCl3)~: 0:94 (t,3H,J=6.5Hz), 1.24 (d,6H,J=6Hz), 1.27-2.95 (m,31H), 4.19 (m,lH), 5.02 (Hept,lH,J=6Hz) The compounds of the formula I wherein D is -CO-CH2- and those wherein D is -C--C- can be prepared as follows:
Preparation Example 7 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13, 14-dihydro-6,15-diketo-PGF1Qisopropyl ester The compound (43) obtained in Preparation Example 3 is dissolved in a mixture of anhydrous tetrahydrofuran and anhydrous methylenechloride. A small excess amount of N-bromosuccinimide is added to the solution at 0C and the resultant mixture is stirred for 5 minutes. The resultant mixture is worked up with the conventional procedure and the crude product is subjected to column chromatography to give the compound (61) (Q1=Q2=H, Rb-Rc=butyl, P1=tetrahydroxy-pyranyl, P2=ethylene, P3=isopropyl). This is dissolved in anhydrous toluene. The solution is treated with DBU and stirred overnight at 40 C. After cooling with ice, the solution is acidified with N-HCl, stirred for 10 minutes and extracted with ethyl acetate. The resultant mixture is worked up with the conventional procedure and the residue is subjected to column chromatography to give the compound (62) (symbols having the same meaning as above). Removal of the protective groups in a manner similar to that in the step 3-3) in Preparation Example 3 gives the titled compound.
~,~
-Preparation Example 8 Preparation of 2-decarboxy-2-(2-carboxyethyl)-5,6-dehydro-13,14-dihydro-15-keto-PGE2methyl ester Tert-butyl lithium is added dropwise to a solution of 8-5 methoxy-3,3-ethylenedioxy-1-iodooctane (prepared according to JP-A-52753/1989) in ether at -78C over 30 minutes and the resultant mixture is stirred for 3 hours. Then a solution, cooled to -78~C, of cuprous iodide and tributylphosphine in ether is added to the above mixture in one portion and the resultant mixture is stirred for 20 minutes to form the complex (a). A solution of 4R-tert-butyldimethylsilyloxy-2-cyclopenten-1-one (63) in tetrahydrofuran is added dropwise to the mixture over 95 minutes. The resultant mixture is stirred for 15 minutes and transferred to a cooling bath at -30C. A
solution of $-methoxycarbonyl-1-iodooctyne (b) in HMPA is added to the cooled mixture, which is then stirred for 4.5 hours. Stirring is continued at the room temperature for 12 hours and then the mixture is poured into an aqueous ammonium chloride solution. The organic layer is separated and worked up with the conventional procedure to give a crude product.
The crude product is subjected to column chromatography to give the compound (64) [Q1=Q2=H, Rb-Rc=butyl, P3=methyl, P5=
tert-butyldimethylsilyl]. Deprotection of this in the conventional manner gives the titled compound.
Preparation Example 9 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-16,16-difluoro-15-keto-PGF2amethyl ester (72) [IUPAC
nomenclature: methyl (Z)-9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl)-3,5-dihydroxycyclopentyl]-7-nonenoate 9-1) Preparation of (lS,5R,6R,7R)-6-[3(R,S)-t-butyldimethyl-silyloxy-4,4-difluorooctyl]-7-(tetrahydropyranyloxy)-2-oxabicyclo[3.3.0]octan-3(R,S)-ol (66) The compound (52) [Q1=Qz=F, P1=tetrahydropyranyl, Rb-Rc=butyl] (1.26g) was treated with imidazole (2.63g) and tert-butyldimethylsilyl chloride (2.91g) in DMF (15ml) to give the silyl ether (65). Yield: 1.43g (88%).
The silyl ether (65) (1.43g) was reduced with diisobutyl-.~
203 ~420 aluminum hydride in the conventional procedure to give the titled compound (66). Yield: 1.47g (100%).
9-2) Preparation of methyl (Z)-9-(lR)-[(2R,3R,5S)-2-{3(R,S)-tert-butyldimethylsilyloxy-4,4-difluorooctyl~-5-hydroxy-3-(tetrahydropyranyloxy)cyclopentyl]-7-nonenoate (68) A ylid was prepared from sodium hydride (60%, 0.934g), DMSO (25ml) and (6-carboxyhexyl)triphenylphosphonium bromide (5.50g) in the conventional procedure. The ylid was added to a solution of the compound (66) in ether (8ml) and the resultant mixture was stirred at room temperature for 2 hours.
The resultant mixture was worked with the conventional procedure to give the carboxylic acid (67), which was treated with diazomethane. The product was then subjected to silica gel column chromatography to give the titled compound (68).
Yield: 0.43g (48%).
9-3) Preparation of methyl (Z)-9-(lR)-t(2R,3R,5S)-2-{3(R,S)-tert-butyldimethylsilyloxy-4,4-difluorooctyl}-3,5-(ditetrahydropyranyloxy)cyclopentyl]-7-nonenoate (69) The compound (68) (0.438g) was converted to ditetrahydropyranyl ether using an excess amount of dihydropyran and a catalytic amount of p-toluenesulfonic acid in dichloromethane (25ml). The resultant mixture was subjected to silica gel column chromatography to give the compound (69). Yield: 0.494g (99%).
9-4) Preparation of methyl (Z)-9-(lR)-[(2R,3R,5S)-2-(tert-butyldimethylsilyloxy-3-oxooctyl)-3,5-(ditetrahydro-pyranyloxy)cyclopentyl]-7-nonenoate (71) The compound (69) (0.494g) was dissolved in THF (lOml), tetrabutylammonium trifluoride (l.OM, 5.6ml) added to the solution, and the resultant mixture was kept overnight. The resultant mixture was then worked up with the conventional procedure to give the deprotected compound (70).
Yield: 0.284g (68%).
The compound (70) (0.284g) was subjected to Swern oxidation using oxalyl chloride (0.165ml) and DMSO (0.3ml) in dichloromethane (lOml). The product was subjected to silica gel column chromatography to give the compound (71).
,~.
.
Yield: 0.251g (89%).
9-5) Preparation of methyl (Z)-9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl)-3,5-dihydroxycyclopentyl]-7-nonenoate (72) The compound (71) was dissolved in a mixed solvent (3Oml) consisting of acetic acid, water and THF (4:2:1) and the solution was kept at 45 to 50C for 3 hours. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (72).
Yield: 0.137 (76%).
Compound (72) [Q1=Q2=F, Rb-Rc=butyl, P3=methyl]
H NMR(CDC13)S: O.g2 (t,3H,J=7.5Hz), 1.2-2.9 (m,38H), 3.67 (s,3H), 3.70 (q,lH,J=7.5Hz), 4.25 (m,lH), 5.43 (m,2H) Preparation Example 10 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-16,16-difluoro-15-keto-PGEl(73) [IUPAC nomenclature:
(Z)-9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]nonanoic acid]
10-1) Preparation of benzyl (Z)-9-(lR)-[(2R,3R,5S)-3-{4,4-difluoro-3(R,S-hydroxyoctyl}-5-hydroxy-3-(tetrahydro-pyranyloxy)cyclopentyl]-7-nonenoate (55) The compound (54) [Q1=Q2=F, P1=tetrahydropyranyl, Rb-Rc=butyl] (1.09g) was dissolved in acetonitrile (20ml), and DBU (2.6 ml) and benzyl bromide (2.2ml) were added to the solution. The resultant mixture was kept at 45C for 1 hour and then overnight at 60C. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (65). Yield: 0.213g.
10-2) Preparation of benzyl (Z)-9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl-3-tetrahydropyranyloxy)-5-oxocyclopentyl]-7-nonenoate (56) The compound (55) (0.213g) was subjected to Swern oxidation using oxalyl chloride (0.23ml), DMSO (0.41ml) and triethylamine (0.8lml) in dichloromethane (15ml). The product was subjected to silica gel column chromatography to give the .~ , .
titled compound (56). Yield: 0.181g (86%).
10-3) Preparation of benzyl (Z)-9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl]-7-nonenoate (46) The compound (56) (0.181g) was dissolved in a mixed solvent (25ml) consisting of acetic acid, water and THF
(4:2:1) and the solution was kept at 45C for 3.5 hours. The resultant mixture was worked up with the conventional procedure and the obtained crude product was subjected to silica gel column chromatography to give the titled compound (46). Yield: 0.40g (91%).
Compound (46) [Q1=Q2=F, Rb-Rc=butyl, P3=benzyl]
H NMR(CDC13)~: 0.93 (t,3H,J=7.5Hz), 1.2-2.8 (m,27H), 4.20 (m,lH), 5.12 (s,2H), 5.2-5.5 (m,2H), 7.35 (m,5H) 10-4) Preparation of 9-(lR)-[(2R,3R,5S)-2-(4,4-difluoro-3-oxooctyl-3-hydroxy-5-oxocyclopentyl]nonanoic acid (73) The compound (46) was dissolved in ethyl acetate (15ml). Palladium on carbon (50mg) was added to the solution and shaken under the hydrogen atmosphere. After removing the catalyst by filtration, the filtrate was concentrated and the produced crude product was subjected to Lobar column (ODS) chromatography to give the titled compound (73).
Yield: 0.077g (65%).
Compound (73) [Q1=Q2=F, Rb-Rc=butyl]
1H NMR(CDC13) ~: 0.95 (t,3H,J=7.5Hz), 1.2-2.8 (m,32H), 4.20(m,lH) Preparation Example 11 Preparation of 20-ethyl-2-decarboxy-2-(2-carboxy-ethyl) -13,14-dihydro-16,16-difluoro-15-keto-PGE1isopropyl ester (60) [IUPAC nomenclature: isopropyl (Z)-9-(lR)-[(2R,3R)-2-(4,4-difluoro-3-oxodecyl)-3-hydroxy-5-oxocyclopentyl]-7-nonenoate]
The procedure of Preparation Example 6 was repeated except that dimethyl (3,3-difluoro-2-oxononyl)-phosphonate was used to give the titled compound (60). Compound (60) [Q1=Q2=F, Rb-Rc=hexyl, P3=isopropyl]
1H NMR(CDCl3)~: 0.90 (t,3H,J=7.5Hz), 1.32 (d,6H,J=6Hz), 1.25-2.70 (m,34H), 3.15 (s,lH), 4.20 (m,lH), 5.00 (Hept,lH,J=7.5Hz) ~.~
20J~420 .
Preparation Example 12 Preparation of 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-PGE2isopropyl ester (46) [IUPAC nomenclature:
isopropyl (Z)-9-(lR)-[(2R,3R)-2-(3-oxopentyl)-3-hydroxy-5-oxocyclopentyl]-7-nonenoate]
The procedure of Preparation Example 4 was repeated except that dimethyl 2-oxoheptylphosphonate was used to give the titled compound (46).
Compound (46) [Q1=Q2=H, Rb-Rc=butyl, P3=isopropyl]
1H NMR(CDCl3)~: 0.89 (t,3H,J=6.6Hz), 1.18 (d,6H,J=6.2Hz), 1.15-3.0 (m,29H), 4.04 (m,lH), 4.99 (hept,IH, J=6.2Hz), 5.37 (m,2H) Formulation Example 1 (Powders for injection) (Parts by weight) 13,14-dihydro-15-keto-16,16-difluoro-PGE2 mannitol 5 distilled water 0.4 The above ingredients were mixed, stirred, sterilized, 20 filtered and lyophilized to give powders for injection.
Formulation Example 2 (Injectable solution) (Parts by weight) 13,14-dihydro-15-keto-16,16-difluoro-PGE1 0.2 nonion surfactant 2 distilled water 98 The above ingredients were mixed and sterilized to give an injectable solution.
Formulation Example 3 (Enteric capsules) 13,14-dihydro-15-keto-16,16-difluoro-20-methyl-PGE2 (50mg) dissolved in methanol (lOml) was mixed with mannitol (18.5g).
The mixture was screened (with a sieve, the pore size of which being 30 mm in diameter), dried at 30C for 90 minutes and screened again. The powders thus obtained were mixed with fine-grain silica gel (Aerosil*, 200g) and filled in No.3 hard * Trade-Mark gelatin capsules (100) to give enteric capsules which contain 0.5mg of 13,14-dihydro-15-keto-16,16-difluoro-20-methyl-PGE2 per capsule.
Formulation Example 4 (Powders for oral administration) (Parts by weight) 13,14-dihydro-6,15-diketo-16,16-difluoro-PGE1methyl ester 5 light anhydrous silicic acid 5 Abicel* 20 lactose 70 The above ingredients were mixed to give powders for oral administration.
Formulation ExamPle 5 (Soft gelatine capsules) (Parts by weight) 13,14-dihydro-6,15-diketo-l9-methyl-PGE
methyl ester light anhydrous silicic acid 899 Panasate* 20 The above ingredients were mixed and filled in soft gelatine capsules.
Formulation Example 6 (Enteric capsules) 16-desbutyl-13,14-dihydro-15-keto-16-m-trifluoromethyl-phenoxy-PGFzQmethyl ester (50mg) dissolved in methanol (lOml) was mixed with mannitol (18.5g). The mixture was screened (with a sieve, the pore size of which being 30 mm in diameter), dried at 30C for 90 minutes and screened again.
The powders thus obtained were mixed with fine-grain silica gel (Aerosil , 200g) and filled in No.3 hard gelatin capsules (100) to give enteric capsules which contain 0.5mg of 13,14-dihydro-15-keto-16-desbutyl-16-m-trifluoromethylphenoxy-PGF
methyl ester per capsule.
*Trade-Mark p~.,:, Formulation Example 7 (powders for injection) (Parts by weight) 13,14-dihydro-15-keto-16,16-difluoro-PGE1 1 mannitol 5 distilled water 0.4 The above ingredients were mixed, stirred, sterilized, filtered and lyophilized to give powders for injection.
Formulation Example 8 (Injectable solution) (Parts by weight) 13,14-dihydro-6,15-diketo-5R,S-difluoro-PGE1 0.2 nonion surfactant 2 distilled water 98 The above ingredients were mixed and sterilized to give an injectable solution.
Formulation Example 9 (Powders for oral administration) (Parts by weight) 13,14-dihydro-15-keto-16,16-difluoro-l9-desmethyl-PGE2 methyl ester 5 light anhydrous silicic acid 5 - Abicel* 20 lactose 70 The above ingredients were mixed to give powders for oral administration.
Formulation Example 10 (Soft gelatine capsules) (Parts by weight) 13,14-dihydro-15-keto-16-desbutyl-16-m-trifluoromethylphenoxy-PGE2methyl ester light anhydrous silicic acid 899 Panasate* 20 The above ingredients were mixed and filled in soft gelatine capsules.
* Trade-Mark A~
~ 53 2039420 In the above formulation examples, the active ingredient can be replaced by any other compound within the compounds used in the invention.
Formulation Example 11 (Ophthalmic solution) 13,14-dihydro-15-keto-20-ethyl-PGF2~ 10 mg Physiological Saline 10 ml The above components were placed in separate vials. The vials were combined for preparing a solution on actual use.
Test Example 1 Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 3 groups, each group consisting of 5 or 6 animals (i.e. 10 or 12 eyes). The group 1 was assigned to the normal control group and fed with normal diet. The groups 2 and 3 were fed with 50% galactose diet.
The group 2 subcutaneously received 2 times 5 ml/kg doses (morning and evening) of pure physiological saline, while the group 3 received similarly 2 times doses of 10~g/kg test compound dissolved in 5mg/kg physiological saline. As the test compound, 13,14-dihydro-15-keto-16,16-difluoro-PGE2was used.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque as compared with nuclei of the group 1 animals (control) was taken as the day of onset of cataract. The results are shown in Table 1, in which the numerical values indicate cataract/total eyes.
Table 1 Group (n) Day 1 (6)0/12 - 0/12 0/12 0/12 0/12 0/12 2 (5)0/10 - 0/10 1/10 2/10 5/10 7/10 3 (6)0/12 - 0/12 0/12 0/12 1/12 1/12 It can be seen from the above results that the test compound has an activity inhibiting experimental cataract.
Test Example 2 Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 5 groups, each group consisting of 6 animals (i.e. 12 eyes). Each group was fed with 30% galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
Group Substance Dose/Administration Mode 1 Physiological Saline 5tl/eye ophthalmic 2 Test Compound 1 O.ltg/eye ophthalmic 3 Test Compound 1 lOtg/kg subcutaneous 4 Test Compound 2 6tg/eye ophthalmic 5 Test Compound 3 lOOtg/kg subcutaneous Test Compounds:
1: 13,14-dihydro-15-keto-16,16-difluoro-PGE2methyl ester 2: 13,14-dihydro-15-keto-20-ethyl-PGF2aisopropyl ester 3: 13,14-dihydro-15-keto-20-ethyl-PGF2a The ophthalmic administration was effected with a solution of the test compound dissolved in a physiological saline (5tl/eye), administered 3 times a day. The subcutaneous administration was effected with a solution of the test compound in a physiological saline (5ml/kg), administered twice a day.
The results are shown in Table 2, in which the numerical values indicate cataract/total eyes.
Table 2 Group Day 2039 ~ 20 It can be seen from the above results that the test compounds have an activity inhibiting experimental cataract.
Test ExamPle 3 Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 3 groups, each group consisting of 6 animals (i.e. 12 eyes). Each group was fed with 30% galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
Group Substance Dose/Administration Mode 1 Physiological Saline 5tl/eye ophthalmic 2 Test Compound 4 O.ltg/eye ophthalmic 3 Test Compound 4 lOtg/kg subcutaneous Test Compound:
4: 13,14-dihydro-15-keto-16,16-difluoro-PGE2isopropyl ester The ophthalmic administration was effected with a solution of the test compound dissolved in a physiological saline (5tl/eye), administered 3 times a day. The subcutaneous administration was effected with a solution of the test compound in a physiological saline (5ml/kg), administered twice a day.
The results are shown in Table 3, in which the numerical values indicate rate (in %) of onset of cataract (cataract x 100/total eyes).
Table 3 Group Day It can be seen from the above results that the test compounds have an activity inhibiting experimental cataract.
^~--~ 56 2039¢20 Test Example 4 Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 3 groups, each group consisting of 6 animals (i.e. 12 eyes). Each group was fed with 30% galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
Group Substance Dose/Administration Mode 1 Physiological Saline 5ml/kg subcutaneous 2 Test Compound 5 O.ltg/eye ophthalmic 3 Test Compound 5 lOtg/kg subcutaneous Test Compounds:
5: 13,14-dihydro-15-keto-16,16-difluoro-PGE1methyl ester The ophthalmic administration was effected with a solution of the test compound dissolved in a physiological saline (5tl/eye), administered 3 times a day. The subcutaneous administration was effected with a solution of the test compound in a physiological saline (5ml/kg), administered 4 times a day.
The results are shown in Table 4, in which the numerical values indicate rate (in %) of onset of cataract (cataract x 100/total eyes).
Table 4 Group Day It can be seen from the above results that the test compounds have an activity inhibiting experimental cataract.
A~.
~..
Test ExamPle 5 (ComParative) Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 7 groups. Each group was fed with 40~ galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
Group Substance Animal (eye) Dose/Administration 1 Physiological Saline 10(20) 5ml/kg 2 Test Compound 6 5(10)lOOtg/kg 3 Test Compound 7 5(10)lOOtg/kg 4 Test Compound 8 5(10)lOOtg/kg 5 Test Compound 9 5(10)lOOtg/kg 6 Test Compound 10 5(10)lOtg/kg 7 Test Compound 11 5(10)ltg/kg Test Compounds:
6: PGE1 7: PGDz 8: PGF2a 9: PGA2 10: 16,16-dimethyl-PGE2 11: 6-oxo-17S,20-dimethyl-PGE1 The administration was effected with a solution of the test compound in a physiological saline (5ml/kg), substaneously administered twice a day.
The results are shown in Table 5, in which the numerical values indicate rate (in %) of onset of cataract (cataract x 100/total eyes).
q~ , 203~420 Table 5 Group Day 7 o - O 30 6070 70 It can be seen from the above results that the primary type PGs having a hydroxy group at position 15 have no distinct inhibition and in some cases have, rather, promotion to cataract.
Test Example 6 Wistar rats (3 weeks old, weight: 40 to 50g) were allotted into 4 groups, each group consisting of 9 animals (i.e. 18 eyes). Each group was fed with 30% galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
Group Substance Dose/Administration 1 Physiological Saline 5tl/eye 2 Test Compound 12 O.ltl/eye 3 Test Compound 13 O.ltg/eye 4 Test Compound 14 l.Otg/eye Test Compounds:
12: 13,14-dihydro-15-keto-16,16-difluoro-19-desmethyl-PGE2 methyl ester .~
13: 13,14-dihydro-15-keto-16,16-difluoro-20-methyl-PGEz methyl ester 14: 13,14-dihydro-15-keto-16,16-difluoro-20-ethyl-PGE2 methyl ester The administration was effected with a solution of the test compound in a physiological saline (5tl/eye), administered 3 times a day. The control group received a physiological saline (5tl/eye).
The results are shown in Table 6, in which the numerical values indicate rate (in %) of onset of cataract (cataract x 100/total eyes).
Table 6 Group Day It can be seen from the above results that the test compounds have an activity inhibiting experimental cataract.
Test Example 7 Wistar rats (3 weeks old, weight: 50 to 60g) were allotted into 6 groups, each group consisting of 9 animals (i.e. 18 eyes). Each group was fed with 30% galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
203~ 420 Group Substance Dose/Administration 1 Physiological Saline 5ml/kg 2 Test Compound 15 lOtg/kg 3 Test Compound 16 lOtg/kg 4 Test Compound 17 lOtg/kg Test Compound 18 lOtg/kg 6 Test Compound 19 lOtg/kg Test Compounds:
The results are shown in Table 6, in which the numerical values indicate rate (in %) of onset of cataract (cataract x 100/total eyes).
Table 6 Group Day It can be seen from the above results that the test compounds have an activity inhibiting experimental cataract.
Test Example 7 Wistar rats (3 weeks old, weight: 50 to 60g) were allotted into 6 groups, each group consisting of 9 animals (i.e. 18 eyes). Each group was fed with 30% galactose diet.
The eyes of the rats were observed every day and the day on which the nucleus of crystalline lens was distinctly opaque.
Test design was as follows:
203~ 420 Group Substance Dose/Administration 1 Physiological Saline 5ml/kg 2 Test Compound 15 lOtg/kg 3 Test Compound 16 lOtg/kg 4 Test Compound 17 lOtg/kg Test Compound 18 lOtg/kg 6 Test Compound 19 lOtg/kg Test Compounds:
15: 13,14-dihydro-15-keto-16,16-difluoro-PGE1 isopropyl ester 16: 13,14-dihydro-15-keto-16,16-difluoro-20-ethyl-PGE
isopropyl ester 17: 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16,16-difluoro-PGE1 isopropyl ester 18: 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16,16-difluoro-20-ethyl-PGE1isopropyl ester 19: 13,14-dihydro-15-keto-16,16-dimethyl-PGE2ethyl ester The administration was effected with a solution of the test compound in a physiological saline (5ml/kg), administered twice a day. The control group received a physiological saline (5ml/kg).
The results are shown in Table 7, in which the numerical values indicate rate (in %) of onset of cataract (cataract x 100/total eyes).
'~.' . -~ 61 2039420 Table 7 Group Day o - 6 11 22 It can be seen from the above results that the test compounds have an activity inhibiting experimental cataract.
,~
isopropyl ester 17: 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16,16-difluoro-PGE1 isopropyl ester 18: 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16,16-difluoro-20-ethyl-PGE1isopropyl ester 19: 13,14-dihydro-15-keto-16,16-dimethyl-PGE2ethyl ester The administration was effected with a solution of the test compound in a physiological saline (5ml/kg), administered twice a day. The control group received a physiological saline (5ml/kg).
The results are shown in Table 7, in which the numerical values indicate rate (in %) of onset of cataract (cataract x 100/total eyes).
'~.' . -~ 61 2039420 Table 7 Group Day o - 6 11 22 It can be seen from the above results that the test compounds have an activity inhibiting experimental cataract.
,~
Claims (14)
1. A pharmaceutical composition for the treatment of cataracts comprising a 15-ketoprostaglandin compound in association with a pharmaceutically acceptable carrier, diluent or excipient.
2. A composition according to claim 1, in which said 15-ketoprostaglandin compound is a 16-mono- or di-halo-15-ketoprostaglandin compound.
3. A composition according to claim 1, in which said 15-ketoprostaglandin compound is a 13,14-dihydro-16-mono- or di-halo-15-ketoprostaglandin compound.
4. A composition according to claim 1, in which said 15-ketoprostaglandin compound is a 13,14-dihydro-16-mono- or di-fluoro-15-ketoprostaglandin compound.
5. A composition according to claim 1, in which said 15-ketoprostaglandin compound is a 15-keto-20-loweralkyl-prostaglandin compound.
6. A composition according to claim 1, in which said 15-ketoprostaglandin compound is a 13,14-dihydro-15-keto-20-loweralkyl-prostaglandin compound.
7. A compound of the formula:
(I) wherein L and M are hydrogen atom, hydroxy, lower alkyl, hydroxy(lower)alkyl or oxo, provided that at least one of L and M is not hydrogen atom and that the five-membered ring may have one or two double bonds, Q1 and Q2 are hydrogen atom, halogen atom or lower alkyl, D is -CH2-CH2-, -CH=CH-, -CC- or -CO-CH2-, E is -CH2-CH2- or -CH=CH-, W is - CH2-CH2-CH2-, - CH=CH-CH2 or -CH2- CH=CH -, Ra is hydrogen atom, lower alkyl, lower cycloalkyl, monocyclic aryl, monocyclic aryl(lower)alkyl or monocyclic aroyl(lower) alkyl, Rb is single bond or lower alkylene, Rc is lower alkyl which is unsubstituted or substituted with halogen, lower cycloalkyl which is unsubstituted or substituted with lower alkyl, monocyclic aryl which is unsubstituted or substituted with halogen or halo(lower)alkyl, or monocyclic aryloxy which is unsubstituted or substituted with halogen or halo(lower)alkyl, or a pharmaceutically acceptable salt when Ra is hydrogen atom, provided that Ra is not H or lower alkyl if the following conditions are simultaneously satisfied D is - CH=CH - or -CH2-CH2-E is - CH=CH -L is -OH
M is -OH
Q1 is H
Q2 is H
W is - CH2-CH2-CH2--Rb-Rc is -(CH2)3-CH3
(I) wherein L and M are hydrogen atom, hydroxy, lower alkyl, hydroxy(lower)alkyl or oxo, provided that at least one of L and M is not hydrogen atom and that the five-membered ring may have one or two double bonds, Q1 and Q2 are hydrogen atom, halogen atom or lower alkyl, D is -CH2-CH2-, -CH=CH-, -CC- or -CO-CH2-, E is -CH2-CH2- or -CH=CH-, W is - CH2-CH2-CH2-, - CH=CH-CH2 or -CH2- CH=CH -, Ra is hydrogen atom, lower alkyl, lower cycloalkyl, monocyclic aryl, monocyclic aryl(lower)alkyl or monocyclic aroyl(lower) alkyl, Rb is single bond or lower alkylene, Rc is lower alkyl which is unsubstituted or substituted with halogen, lower cycloalkyl which is unsubstituted or substituted with lower alkyl, monocyclic aryl which is unsubstituted or substituted with halogen or halo(lower)alkyl, or monocyclic aryloxy which is unsubstituted or substituted with halogen or halo(lower)alkyl, or a pharmaceutically acceptable salt when Ra is hydrogen atom, provided that Ra is not H or lower alkyl if the following conditions are simultaneously satisfied D is - CH=CH - or -CH2-CH2-E is - CH=CH -L is -OH
M is -OH
Q1 is H
Q2 is H
W is - CH2-CH2-CH2--Rb-Rc is -(CH2)3-CH3
8. A compound according to claim 7, in which Q1 is a fluorine atom.
9. A compound according to claim 8, in which Q2 is a fluorine atom.
10. A compound according to claim 7, in which E is -CH2-CH2-.
11. A compound according to claim 7, in which Rb is a single bond and Rc is a lower alkyl.
12. A compound according to claim 1, in which L and M are hydrogen atom, hydroxy or oxo and the five-membered ring may have one double bond, Q1 and Q2 are hydrogen atom, fluorine atom or methyl, D is -CH2-CH2-, -CH=CH-, -CC- or -CO-CH2-, E is -CH2-CH2-or -CH=CH-, W is -CH2-CH2-CH2-, Ra is hydrogen atom, methyl, ethyl, isopropyl, benzyl or phenacyl, and Rb-Rc is butyl or hexyl.
13. The use for the treatment of cataracts of a 15-ketoprostaglandin composition.
14. The use of a 15-ketoprostaglandin compound for the manufacture of a medicament for the treatment of cataracts.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP90895/1990 | 1990-04-04 | ||
JP9089590 | 1990-04-04 | ||
JP22164690 | 1990-08-22 | ||
JP221646/1990 | 1990-08-22 | ||
JP29310/1991 | 1991-01-29 | ||
JP2931091 | 1991-01-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2039420A1 CA2039420A1 (en) | 1991-10-05 |
CA2039420C true CA2039420C (en) | 1996-12-10 |
Family
ID=27286510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002039420A Expired - Lifetime CA2039420C (en) | 1990-04-04 | 1991-03-28 | Treatment of cataract with 15-keto-prostaglandin compounds |
Country Status (11)
Country | Link |
---|---|
US (2) | US5212324A (en) |
EP (1) | EP0453127B1 (en) |
KR (1) | KR970005172B1 (en) |
AT (1) | ATE169219T1 (en) |
AU (1) | AU644148B2 (en) |
CA (1) | CA2039420C (en) |
DE (1) | DE69129921T2 (en) |
DK (1) | DK0453127T3 (en) |
ES (1) | ES2119762T3 (en) |
GR (1) | GR3027666T3 (en) |
TW (2) | TW249226B (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW205508B (en) * | 1990-08-02 | 1993-05-11 | Kabushikaisha Ueno Seiyaku Oyo Kenkyujo | |
US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5352708A (en) * | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5328933A (en) * | 1992-10-28 | 1994-07-12 | Allergan, Inc. | Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues |
SE9303627D0 (en) * | 1993-11-03 | 1993-11-03 | Kabi Pharmacia Ab | Method and means for the prevention of cataract |
DE69434617D1 (en) * | 1993-11-19 | 2006-04-06 | Univ Sydney | PROCEDURE FOR PROPHYLAXIS OR CONTROL OF THE CATARACT |
SE9403160D0 (en) * | 1994-09-21 | 1994-09-21 | Pharmacia Ab | Method and means for prevention and treatment of secondary cataract |
KR19990036322A (en) * | 1996-06-10 | 1999-05-25 | 류지 우에노 | Endothelin antagonist |
US5977173A (en) * | 1997-09-09 | 1999-11-02 | Wos; John August | Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists |
JP4619531B2 (en) * | 1997-09-09 | 2011-01-26 | デューク ユニバーシティ | Aromatic C16-C20 substituted tetrahydroprostaglandins useful as FP agonists |
ES2310013T3 (en) * | 1997-11-28 | 2008-12-16 | Sucampo Ag | USE OF 15-CETO-PROSTAGLANDINE E COMPOUNDS AS ENDOTHELINE ANTAGONISTS. |
AU766163B2 (en) | 1999-03-05 | 2003-10-09 | Duke University | C16 unsaturated fp-selective prostaglandins analogs |
TWI225398B (en) * | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
US6458836B1 (en) | 2000-03-16 | 2002-10-01 | Sucampo, A.G. | Treatment of ocular hypertension and glaucoma |
IL151683A0 (en) * | 2000-03-16 | 2003-04-10 | Sucampo Ag | Composition for use in treatment of ocular hypertension and glaucoma |
JP2003527430A (en) | 2000-03-24 | 2003-09-16 | スカンポ・アクチェンゲゼルシャフト | Apoptosis inhibitor containing 15-ketoprostaglandin or a derivative thereof |
US20020146439A1 (en) * | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
ATE433754T1 (en) * | 2000-04-06 | 2009-07-15 | Sucampo Ag | BALE ACID PROMOTING COMPOSITION FOR LIVER TRANSPLANTATION CONTAINING A 15-KETO PROSTAGLANDIN |
TWI302100B (en) | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
MXPA04001604A (en) * | 2001-08-23 | 2004-07-08 | Sucampo Ag | Method and composition for treatment of ocular hypertension and glaucoma. |
CA2458471C (en) | 2001-08-31 | 2012-07-31 | Sucampo Ag | Prostaglandin analogs as chloride channel opener |
US8580851B2 (en) * | 2002-08-21 | 2013-11-12 | Sucampo Ag | Ophthalmic solution |
PT1562604E (en) * | 2002-10-23 | 2012-04-09 | Sucampo Ag | Prostaglandin compounds for the treatment of obesity |
BRPI0317740B8 (en) | 2002-12-27 | 2021-05-25 | Sucampo Ag | use of the compound 13,14-dihydro-15-keto-16,16-difluoroprostaglandin e1 |
WO2005002588A1 (en) * | 2003-07-03 | 2005-01-13 | Sucampo Ag | Enteric coated composition comprising prostaglandin analogs as chloride channel opener |
TWI495471B (en) * | 2003-08-12 | 2015-08-11 | R Tech Ueno Ltd | Composition and method for promoting hair growth |
KR20120005052A (en) | 2003-08-21 | 2012-01-13 | 수캄포 아게 | Ophthalmic composition |
SE0303179D0 (en) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
JP4690814B2 (en) * | 2004-08-02 | 2011-06-01 | 株式会社アールテック・ウエノ | Method for producing prostaglandin derivatives |
AR055846A1 (en) | 2005-01-27 | 2007-09-12 | Sucampo Ag | COMPOSITE OF PROSTAGLANDINA AND METHOD TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS |
EP2308495A1 (en) | 2005-03-04 | 2011-04-13 | Sucampo AG | Method and composition for treating peripheral vascular diseases |
WO2010102078A1 (en) | 2009-03-04 | 2010-09-10 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
US20060281818A1 (en) | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
WO2006109881A1 (en) * | 2005-04-12 | 2006-10-19 | Sucampo Ag | Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders |
CA2637275C (en) * | 2006-01-24 | 2014-12-09 | R-Tech Ueno, Ltd. | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
RU2420291C3 (en) | 2006-01-24 | 2020-07-21 | Р-Тек Уено, Лтд. | COMPOSITION IN SOFT GELATIN CAPSULE |
KR101382922B1 (en) * | 2006-03-13 | 2014-04-08 | 가부시키가이샤 아루떼꾸 우에노 | Aqueous composition |
US8871752B2 (en) * | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
US8722739B2 (en) * | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8623918B2 (en) * | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8609729B2 (en) | 2009-04-15 | 2013-12-17 | Sucampo Ag | Method for treating macular degeneration |
US8569279B2 (en) * | 2009-05-27 | 2013-10-29 | Sucampo Ag | Method for modulating claudin mediated functions |
US9084815B2 (en) * | 2009-09-16 | 2015-07-21 | Sucampo Ag | Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor |
US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
WO2012137987A1 (en) | 2011-04-07 | 2012-10-11 | Sucampo Ag | Method for treating asthenopia |
KR20140076551A (en) | 2011-08-05 | 2014-06-20 | 수캄포 아게 | Method for treating schizophrenia |
AR092821A1 (en) | 2012-04-20 | 2015-05-06 | Sucampo Ag | CONJUGATE OF GRASO-POLYMER ACID DERIVATIVE |
US20150057351A1 (en) | 2013-08-22 | 2015-02-26 | Sucampo Ag | Method for treating neuropathic pain |
US20170020890A1 (en) | 2015-06-19 | 2017-01-26 | Sucampo Ag | Pharmaceutical composition comprising fatty acid derivative |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3505386A (en) * | 1965-12-29 | 1970-04-07 | Upjohn Co | Compounds related to prostaglandins |
US3974195A (en) * | 1974-10-02 | 1976-08-10 | The Upjohn Company | 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs |
EP0153858A3 (en) * | 1984-02-29 | 1985-12-11 | The Upjohn Company | The therapeutic use of prostaglandins |
CA1322749C (en) * | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
CA1323364C (en) * | 1987-01-28 | 1993-10-19 | Ryuzo Ueno | Prostaglandins e and anti ulcer agents containing same |
CA1324129C (en) * | 1987-04-30 | 1993-11-09 | Ryuzo Ueno | Prostaglandins of the f series |
DE3869471D1 (en) * | 1987-05-15 | 1992-04-30 | Ueno Seiyaku Oyo Kenkyujo Kk | Fever-increasing composition. |
DE3876050T2 (en) * | 1987-09-18 | 1993-03-25 | R Tech Ueno Ltd | OCULAR HYPOTENSIVAGENTS. |
ES2051862T3 (en) * | 1987-10-02 | 1994-07-01 | Ueno Seiyaku Oyo Kenkyujo Kk | A METHOD TO PRODUCE A DRUG THAT HAS A CATARTICAL EFFECT. |
JP2597629B2 (en) * | 1988-02-26 | 1997-04-09 | 株式会社 上野製薬応用研究所 | Stabilization of 13,14-dihydro-15-ketoprostaglandins |
JP2597649B2 (en) * | 1988-05-11 | 1997-04-09 | 株式会社上野製薬応用研究所 | Trachea / bronchodilator |
AU619543B2 (en) * | 1988-05-11 | 1992-01-30 | Sucampo Ag | Use of 15-ketoprostaglandin e or f compounds for uterine contraction |
EP0343904B1 (en) * | 1988-05-23 | 1993-04-28 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Hypersphyxia causing composition |
AU604156B2 (en) * | 1988-09-14 | 1990-12-06 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
ATE162074T1 (en) * | 1988-10-01 | 1998-01-15 | R Tech Ueno Ltd | OCULAR HYPOTENSIVE AGENTS |
TW205508B (en) * | 1990-08-02 | 1993-05-11 | Kabushikaisha Ueno Seiyaku Oyo Kenkyujo |
-
1991
- 1991-03-28 TW TW081106617A patent/TW249226B/zh not_active IP Right Cessation
- 1991-03-28 CA CA002039420A patent/CA2039420C/en not_active Expired - Lifetime
- 1991-03-28 TW TW080102419A patent/TW224942B/zh not_active IP Right Cessation
- 1991-04-03 EP EP91302925A patent/EP0453127B1/en not_active Expired - Lifetime
- 1991-04-03 ES ES91302925T patent/ES2119762T3/en not_active Expired - Lifetime
- 1991-04-03 DK DK91302925T patent/DK0453127T3/en active
- 1991-04-03 AT AT91302925T patent/ATE169219T1/en not_active IP Right Cessation
- 1991-04-03 US US07/680,187 patent/US5212324A/en not_active Expired - Lifetime
- 1991-04-03 AU AU74047/91A patent/AU644148B2/en not_active Expired
- 1991-04-03 DE DE69129921T patent/DE69129921T2/en not_active Expired - Lifetime
- 1991-04-04 KR KR1019910005502A patent/KR970005172B1/en not_active IP Right Cessation
-
1994
- 1994-09-06 US US08/300,541 patent/US5686487A/en not_active Expired - Lifetime
-
1998
- 1998-08-19 GR GR980400874T patent/GR3027666T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU7404791A (en) | 1991-10-10 |
EP0453127A2 (en) | 1991-10-23 |
ATE169219T1 (en) | 1998-08-15 |
KR910018027A (en) | 1991-11-30 |
TW249226B (en) | 1995-06-11 |
GR3027666T3 (en) | 1998-11-30 |
EP0453127B1 (en) | 1998-08-05 |
DK0453127T3 (en) | 1998-10-26 |
US5212324A (en) | 1993-05-18 |
ES2119762T3 (en) | 1998-10-16 |
TW224942B (en) | 1994-06-11 |
CA2039420A1 (en) | 1991-10-05 |
KR970005172B1 (en) | 1997-04-14 |
DE69129921T2 (en) | 1999-01-14 |
US5686487A (en) | 1997-11-11 |
EP0453127A3 (en) | 1992-12-09 |
DE69129921D1 (en) | 1998-09-10 |
AU644148B2 (en) | 1993-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2039420C (en) | Treatment of cataract with 15-keto-prostaglandin compounds | |
US5432174A (en) | Treatment of ocular hypertension | |
EP0503887B1 (en) | Promotion of wound-healing with 15-keto-prostaglandin compounds | |
US5164415A (en) | Treatment of pancreatic disease with 15-keto-prostaglandin compounds | |
EP0467564B1 (en) | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds | |
EP0342003B1 (en) | Use of 15-ketoprostaglandin e or f compounds for uterine contraction | |
EP0458588A1 (en) | Treatment of ocular hypertension with a synergistic combination for ocular administration | |
US5397797A (en) | Treatment of ocular hypertension with an ocular synergistic combination | |
KR0127297B1 (en) | The pharmaceutical compositions of 15-keto-prostaglandin compounds for treatment of hepatobilliary disease | |
CA2042937C (en) | Treatment of ocular hypertension with a synergistic combination | |
EP0430551B1 (en) | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds | |
EP0458587B1 (en) | Synergistic combination for ophthalmic use | |
EP0469782B1 (en) | Treatment of cataract with prostacyclin compounds | |
US5175189A (en) | Treatment of ocular hypertension with a synergistic combination for ophthalmic use | |
EP0410646B1 (en) | Treatment of hyperlipidemia with 15-keto-prostaglandin compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |